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Abstract:
This document provides a summary of the Dutch S3-guidelines on the treatment of psoriasis.
These guidelines were finalized in December 2011 and contain unique chapters on the treatment
of psoriasis of the face and flexures, childhood psoriasis as well as the patient’s perspective on
treatment. They also cover the topical treatment of psoriasis, photo(chemo)therapy, conventional
systemic therapy and biological therapy.
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Abstract 
This document provides a summary of the Dutch S3-guidelines on the treatment of psoriasis. These guidelines were finalized in 
December 2011 and contain unique chapters on the treatment of psoriasis of the face and flexures, childhood psoriasis as well as 
the patient’s perspective on treatment. They also cover the topical treatment of psoriasis, photo(chemo)therapy, conventional 
systemic therapy and biological therapy. 
Abbreviations 
BCC  Basal Cell Carcinoma 
BSA  Body Surface Area 
CIN  Cervical Intraepithelial Neoplasia 
Cr  Chromium 
DLQI  Dermatology Life Quality Index 
EDTA  EthyleneDiamineTetraacetic Acid 
EL  Evidence Level 
EMA  European Medicines Agency 
FDA  Food and Drug Administration 
GE  Grades of Evidence 
GI  Gastrointestinal 
HAART Highly Active Anti-Retroviral Therapy 
HBsAg  Hepatitis B Surface Antigen 
HBV  Hepatitis B Virus 
HCV  Hepatitis C Virus 
HIV  Human Immunodeficiency Virus 
HRQoL Health Related Quality of Life 
IGRA  Interferon-Gamma Release Assay 
IL  InterLeukin 
ITT  Intention To Treat 
IUD  IntraUterine Divice 
KIN  Keratinocytic Intraepidermal Neoplasia 
LCD  Liquor Carbonis Detergens 
LE  Lupus Erythematosus 
LTBI  Latent TB Infection 
MED  Minimal Erythema Dosage 
MPD  Minimal Phototoxic Dosage 
MTX  Methotrexate 
NSAIDs Non-Steroidal Anti-Inflammatory Drugs 
NYHA  New York Heart Association 
PIIINP  Procollagen type III N-terminal Peptide 
PASI  Psoriasis Area and Severity Index 
PGA  Physician Global Assessment 
PRO  Patient Reported Outcomes 
PUVA  Psoralen (plus) UltraViolet A 
QFT-G  QuantiFeron TB Gold test 
SmPC  Summary of Product Characteristics 
TB  Tuberculosis 
TNF  Tumor Necrosis Factor 
UV  UltraViolet 
VAS  Visual Analogue Scale 
1. Introduction to the guidelines 
J. Zweegers, E.M.G.J. de Jong, Ph.I. Spuls 
1.1 Short introduction to psoriasis 
Psoriasis is a chronic, inflammatory skin disease with a prevalence of 2-3% in the Western population [1, 2]. The most common 
clinical form of psoriasis is the chronic plaque type (90%). Abnormalities of the nails are seen in 50-80% of psoriasis patients and 
20-30% also suffer from psoriatic arthritis. Other subtypes are inverse/genital, facial, scalp, guttate, erythrodermic, pustular, and 
palmoplantar psoriasis. Patients with psoriasis have strongly reduced quality of life scores with a quality of life similar to patients 
with diabetes mellitus, cardiovascular diseases, breast cancer, and depression [3]. Psoriasis is a disease that reaches further than 
the skin and may have systemic symptoms, such as metabolic syndrome. It may be associated with other chronic inflammatory 
diseases such as Crohn’s disease, rheumatoid arthritis, and diabetes mellitus [4]. In psoriasis an abnormal local immune reaction 
can be seen, with a significantly elevated number of activated T-cells and dendritic cells and an enhanced production of cytokines. 
Cytokines that appear in large numbers in psoriatic lesions are TNF-alpha, type 1 and type 2 interferons, IL-12, IL-22, IL-23, and 
IL-17A [1, 5].  
Therapies for psoriasis available in the Netherlands include topical treatments (corticosteroids, calcineurin inhibitors, Vitamin D3 
analogues, coal tar, dithranol, combination preparations), photo(chemo)therapy (UVB, PUVA), and systemic therapies. The 
conventional systemic therapies include methotrexate, cyclosporine, acitretin, and fumaric acid esters. In targeting specific 
elements of the immune system, biologics have been added to the therapeutic armamentarium relatively recently. These expensive 
drugs are indicated for patients with moderate to severe psoriasis after ineffective phototherapy, methotrexate, or cyclosporine 
therapy or when these more common therapies are contraindicated or not being tolerated. Of the biologics, infliximab and 
adalimumab are antibodies against TNF-alpha and etanercept is a soluble TNF-alpha receptor fusion protein. Ustekinumab is a 
monoclonal antibody against the IL-12/IL-23 p40 protein. 
1.2 Update of the Dutch S3-guidelines on the treatment of psoriasis 
In 2003, the Dutch Society of Dermatology and Venereology introduced the first evidence-based guidelines on the treatment of 
psoriasis [6]. In 2006-2007, Germany published their first guidelines based on the Dutch guidelines of 2003 [7]. In 2009, the 
European S3-guidelines from the European Dermatology Forum appeared in the literature and were based on the Dutch, British, 
and German S3-guidelines [8].  
In 2005, the Dutch Society of Dermatology and Venereology updated the practice guidelines from 2003 by updating the literature 
and including biologics to the guidelines. In 2009, these guidelines were revised slightly, specifically to improve the safety around 
prescribing methotrexate. 
In 2011, the Dutch Society of Dermatology and Venereology finalized a complete update of the S3-guidelines on the treatment of 
psoriasis in Dutch, which is available online (Dutch S3-Guidelines on the Treatment of Psoriasis 2011; 
http://www.huidarts.info/documents/uploaded_file.aspx?id=579). Besides an update of the chapters on topical therapy, 
phototherapy, conventional systemic therapy, and biologic therapy for chronic plaque type psoriasis, these guidelines contain new 
chapters on the treatment of psoriasis of the face and flexures, childhood psoriasis, and the patient’s perspective on treatment. The 
European S3-guidelines on the systemic treatment of psoriasis vulgaris by Pathirana, et al. (2009) were used as a basis for the 
Dutch S3-guidelines on the treatment of psoriasis 2011. We will summarize these Dutch S3-guidelines in this article. 
Also in 2011, the Dutch Society for Rheumatology initiated additional, multidisciplinary guidelines (Dutch society of 
Rheumatology, Dermatology and Venereology, Gastroenterology and Hepatology, Physicians for Pulmonology and Tuberculosis 
and Internal Medicine as well as the Dutch Arthritis Association) on the use of biologics in daily practice [9] 
(http://www.reumabond.nl/downloads/algemeen/Mijn%20leven/Medicijnen/Biologicals/Richtlijn_biologicals_geautoriseerd.pdf). 
These multidisciplinary guidelines answer questions on commonly encountered issues relating to treatment with biologics. Topics 
include pregnancy, surgical procedures, travelling abroad, and vaccination. We will not discuss these guidelines here. 
1.3 Goals of the guidelines 
The Dutch S3-guidelines on treatment of psoriasis 2011 contain recommendations in order to aid decision-making on treatment of 
psoriasis in daily practice. The guidelines are based on systematic reviews, primary research, and expert opinions. The guidelines 
are intended for dermatologists, but other personnel involved in treating psoriasis, such as general practitioners, could also benefit 
from it. 
1.4 Composition of the working group 
Dermatologists as well as patient representatives participated in the working group. Academic and peripheral centers had to be 
equally represented. These guidelines were developed independently of pharmaceutical companies. Conflicts of interest of 
working group members are mentioned within these guidelines.   
1.5 Methods 
The working group worked for two consecutive years (8 meetings) on a draft of the Dutch S3-guidelines. The working group 
formulated several key questions, which in combination with the chapters of the European S3-guidelines (Pathirana et al. 2009), 
served as the framework for these guidelines. Existing chapters of the European S3-guidelines were translated and updated. 
Chapters on the treatment of psoriasis of the face and flexures and on the treatment of childhood psoriasis were based on 
additional, separate systematic reviews (10-12). The search strategies executed to develop these guidelines are stated in appendix 
1 of the Dutch S3-guidelines (appendix 1 of the Dutch S3-guidelines, available online: 
http://www.huidarts.info/documents/uploaded_file.aspx?id=579).  
An assessment and literature evaluation form were used to select the relevant literature (appendix 2 of the Dutch S3-guidelines, 
available at http://www.huidarts.info/documents/uploaded_file.aspx?id=579). A full text version of the relevant studies was 
requested. Subsequently, these studies were selected according to inclusion and exclusion criteria and methodological quality 
(Table 1). Grades of evidence (GE) were assessed for selected articles (Table 2). Then, the members of the working group 
formulated conclusions and treatment recommendations based on included studies and provided these conclusions with an 
evidence level (Table 2). The final chapters were discussed and the concept guidelines were published online. Dermatologists 
were able to provide additional comments. These comments were implemented in the final version of the guidelines and approved 
by the Dutch Society of Dermatology and Venereology in December 2011.  
Table 1: In- and exclusion criteria for the performed literature search* 
Inclusion criteria Exclusion criteria Prospective studies (except for psoriasis in children) Case reports (except for psoriasis in children) and abstracts Meta-analysis and studies on induction of 
remission (treatment duration ≤ 16 weeks) 
Studies with intralesional or topical administration of systemic treatment (instead of oral administration) Monotherapy (except for the combination therapies retinoids/phototherapy and topical vitamin D/steroids) 
Old-fashioned equipment 
Dutch, English, French and German studies Studies prescribing drugs that are not being used in the Netherlands Studies with the following parameters: the percentage of patients with nearly 
complete remission (≥ 90%), the percentage of patients with partial 
remission (≥ 75%) (and/or duration of remission and/or percentage of improvement of psoriasis measured by PASI, PGA, global severity, body surface area, clearance) 
Studies on phototherapy of only parts of the body 
Dosing regimen and route of administration have to be stated in studies Methotrexate dosage > 25 mg/week Studies with separate data on psoriasis in adults and in children Acitretin < 0.5 mg/kg/day Studies with well-described separate data on several clinical subtypes of psoriasis or 
in case 75% of studied patients have one clinical subtype of psoriasis 
Cyclosporine > 5 mg/kg/day 
Studies with well-described separate data on levels of severity in patients with 
psoriasis or in case 75% of studied patients have moderate to severe psoriasis 
(PASI ≥ 8, topical therapy not sufficient) 
 
*Note: In case of uncertainty whether a study was performed prospectively the study 
was excluded. To avoid inaccuracy, data on the percentage of patients with ≥ 90% 
remission were not extrapolated to the percentage of ≥ 75% remission. 
Table 2: Grades of Evidence and Evidence Levels 
Grades of Evidence (GE) 
A1 Meta-analysis that includes at least one randomized clinical trial with a grade of 
evidence of A1; the results of the different studies included in the meta-analysis must be consistent 
A2 Randomized, double-blind clinical study of high quality (e.g. sample-size calculation, 
flow chart of patient inclusion, ITT analysis, sufficient size) 
B Randomized clinical study of lesser quality, or other comparative study (e.g. non-randomized cohort or case-control study) 
C Non-comparative study 
D Expert opinion  
Evidence Levels (EL) 
1 One study of level A1 or at least two independently performed studies of level A2 
2 At least two independently performed studies of level B 
3 One study of level A2 or B or studies of level C 
4 Little or no systematic empirical evidence; expert opinions 
 
1.6 Structure of the Dutch S3-Guidelines on the Treatment of Psoriasis 2011 
The Dutch S3-guidelines are divided into different chapters, related to the different treatments of chronic plaque psoriasis, 
psoriasis of the face and flexures, and childhood psoriasis. A separate chapter provides an overview of the patient’s perspective on 
treatment of psoriasis.  
Every chapter starts with the key questions. Subsequently, for each treatment a short introduction is provided, followed by the 
mechanism of action, dosing regimen, efficacy, adverse effects/safety, contraindications, monitoring, conclusions, considerations, 
and treatment recommendations. Conclusions are based on current best evidence (Table 1 and 2). The working group members 
decided to provide conclusions on biologics solely based on grade of evidence A2. Translation of these conclusions into treatment 
recommendations for daily practice was established by the working group by considering different aspects, such as efficacy, 
safety, use, availability, and costs of treatment as well as patients’ and physicians’ preferences. In doing so, the Dutch Society of 
Dermatology and Venereology hopes to increase transparency of the Dutch S3-guidelines. A summary of the considerations of 
these different aspects is given in this article and can be found within the summary tables for each treatment (see below). 
1.7 Legal consequences of the guidelines 
Guidelines are composed in order to guide physicians in providing current, best medical care. The insights on treatment of chronic 
plaque psoriasis as stated in these guidelines are broadly agreed upon in the Netherlands. However, physicians are not legally 
required to follow these recommendations. In individual cases it may be desired or may even be necessary to deviate from the 
recommendations in these guidelines. In doing so, the Dutch physician must argue and document his/her different proceedings and 
if possible involve the patient in the decision-making. 
1.8 Authorization 
The full version of the Dutch S3-guidelines on treatment of psoriasis has been authorized by the Dutch Society of Dermatology 
and Venereology in December 2011.  
The present summary document has been agreed upon by all members of the working group who wrote chapters for the Dutch 
version of the S3-guidelines. The working group members approved this summary document. 
1.9 Revision of the guidelines 
The strength of guidelines lies in their continuous revision. Current medical studies as well as daily practice data and comments by 
users of these guidelines need to be implemented in future chapters. New chapters will be added to the Dutch S3-guidelines after 
updating searches on new developments in psoriasis treatment. 
2. Treatment of psoriasis 
2.1 Choice of treatment 
Deciding which treatment to choose involves the ranking of different criteria. For the topical therapies, phototherapies and 
systemic monotherapies, the working group ranked the different drugs by different criteria, such as the degree of efficacy, safety, 
adverse effects, quality of life/treatment satisfaction, costs of therapy, and follow-up. Efficacy is divided into ≥90%, indicating 
almost complete remission, and ≥ 75%, indicating partial remission. Safety is divided into damage to vital organs, dysfunctions, 
teratogenicity, carcinogenicity after long-term use, toxicity in overdose, and drug interactions. In table 3, ranking is displayed 
from +, indicating less common or less serious, to +++, indicating most frequent or most serious. All criteria have been ranked 
separately for the different psoriatic treatments and cannot be calculated into a total score. 
The working group did not value some of the criteria as more important as others. However, patients were able to value criteria in 
the evaluation of the patient’s perspective (Table 3 and chapter 5). The working group holds the opinion that in choosing 
treatment, the decision has to be made in agreement with the patient and can deviate on individual basis from the norm outlined in 
these guidelines. 
Table 3: Choice of treatment  Efficacy  Safety Advers
e 
effects 
Quality 
of life/ 
Treatm
ent 
satisfac
tion 
** 
Costs of 
therapy 
and 
follow-up 
*** 
 
≥9
0 in % 
 
≥7
5 in % Duratio
n of ii Damag
e to vit
al 
 
Dysfun
ctions*
 
T
er
at
og
en
ic
it
y 
Carcino
genicit
y 
ft l
t 
 
T
ox
ic
it
y 
in d Drug 
    
Topical           +  Calcineurin inhibitors ? ? + 0 0 ? + 0 0 +  + Dithranol 30-
70% 26-100% + 0 0 ? 0 0 0 +  +/++ Corticosteroids 25-78% 25-89% + + + 0 0 0 0 +  0 Coal tar ? 45-
80% + 0 0 ? ? 0 0 0  0 Vitamin D analogues ? 30-50% + 0 0 ? 0 0 0 +  + Vitamin D/corticosteroids 
? 55-
76% + + + ? 0 0 0 +  + 
Phototherap
y        ****   ++  UVB 29-
75% See chapter photot
her. 
++ 0 0 0 + + 0 +  Outpatient: ++ Home: ++ 
PUVA 79% See chapter photot
her. 
++ + + ++/+++ ++ ++/+++ + ++  +++ 
   
 Efficacy  Safety Advers
e 
effects 
Quality 
of life/ 
Treatm
ent 
satisfac
tion 
** 
Costs of 
therapy 
and 
follow-
up 
*** 
 
≥9
0 in % 
 
≥7
5 in % Duratio
n of ii Damag
e to vit
al 
 
Dysfun
ctions*
 
T
er
at
og
en
ic
it
y 
Carcino
genicit
y 
ft l
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T
ox
ic
it
y 
in over
dose 
**** Drug in
teracti
ons    
Systemic           +++  Retinoids 11-
50%* 25-41% +/++ + +/++ +++ 0 +/++ +/++ ++  + Methotrexate 11-
40% 35-73% +/++ ++ ++ ++ + ++/+++ ++/+++ +/++  + Cyclosporine 33% 20-
71% + ++/+++ ++ + ++ +/++ ++/+++ +/++  +/++ Fumaric acid 17-
46% ? ++ +/++ +/++ + 0? +/++ + ++  + Adalimumab 24-
52% 53-80% ++ + + + ++ 0 + +  +++ Etanercept 11-
21% 30-49% + + + + + 0 + +  +++ Infliximab 41-
57% 64-88% ++ + + + ++ 0 + ++  +++ Ustekinumab 36-
51% 66-76% +++ + + + + 0 + +  +++ 
* kidney function disorders, liver function disorders, disorders of fat metabolism+++ more 0 none 
** see chapter “The patient’s perspective”: the groups are judged per group and ++ less ? unclear 
 not per treatment. + least Phototherapy: UVB outpatient ++, UVB home +++, PUVA +  
*** costs reimbursed by insurance company for treatment of 16 weeks 
**** explanation (systemic/phototherapy): phototoxicity, nephrotoxicity, hepatotoxicity. 
2.2 Topical therapies 
P.C.M. van de Kerkhof, R.J. Borgonjen 
Calcineurin inhibitors 
Table 4: Calcineurin inhibitors Recommended initial dosage Tacrolimus (Protopic®) 0.03% ointment, 
followed by 0.1% ointment 1-2x daily 
Pimecrolimus (Elidel®) 1% ointment 1-2x daily Recommended maintenance dosage Apply until clearance of psoriatic lesions is 
reached. Then continue regular skin care 
(i.e., basic treatment, non-medicated ointments) Important adverse effects (See SmPC) Burning sensation Folliculitis, viral skin infections. Prevention/treatment of adverse effects Stop treatment in case of adverse effects 
or intolerable burning sensation. Applying topical corticosteroids or disinfectants will rapidly improve symptoms. Absolute contraindications (See SmPC) Hypersensitivity to calcineurin inhibitor or  any other component of the preparation Primary or secondary immune deficiencies Malignant or premalignant skin lesions Pregnancy and breast feeding Relative contraindications Skin infections (e.g., herpes simplex, 
(See SmPC) folliculitis) UV-light exposure Liver disorder Age <2 years Live vaccines Important drug interactions No known drug interactions Costs 30 g Protopic 0.03% ointment or Elidel 
cream = € 25.79 
Protopic 0.1% ointment = €29.04 Special notes Because of FDA warning: careful when using calcineurin inhibitors combined with phototherapy Due to lack of evidence, do not prescribe calcineurin inhibitors during pregnancy and breast feeding  
Conclusions of the Dutch guidelines      EL: 2 
Calcineurin inhibitors improve psoriasis compared to placebo if 1) the calcineurin inhibitor is being used under occlusion, 2) the calcineurin inhibitor is combined with a drug that enhances skin penetration (e.g. 
salicylic acid gel) or 3) the concentration of the calcineurin inhibitor is at 
least 3 times the registered concentration for atopic dermatitis in the 
Netherlands. It must be noted that included studies used small patient samples and suffered from substantial drop-outs (18-46%). In a larger study no difference was found between tactrolimus gel, tacrolimus 
cream and calcipotriol ointment.  
A2 Ortonne et al., 2006 (13) 
B Carrol et al., 2005 (14)  
Treatment recommendation 
Tacrolimus and pimecrolimus may be used 1-2x daily for chronic plaque type psoriasis in the face, flexures, and anogenital region 
(see chapter: Treatment of psoriasis of the face and flexures) as an additive (interval treatment) or as a replacement of 
corticosteroids. Use on other localizations is not recommended. 
Be alert to adverse effects, such as burning sensation or irritation of the skin. 
Calcineurin inhibitors should not be applied under occlusion or used in combination with UV-therapy. 
Dithranol 
Table 5: Dithranol Recommended initial dosage Conventional therapy (hospitalized patients):  
Initial dosage 0.1% cream or ointment 1x 
daily, applied on the psoriatic lesions. Do 
not rinse the preparation. Double concentration, guided by skin irritation, 
every 3 days until a concentration of 1-3% 
is reached. In case of extreme skin 
irritation, consider lowering dosage. 
Treatment duration: 4-6 weeks; after 2-3 weeks improvement should be noticed. No rebound-effect has been noted when treatment is terminated prematurely.  
Short-contact therapy (non-hospitalized 
patients): Initial dosage 0.1% cream or ointment applied on the psoriatic lesions, 
during 10-30 minutes. Rinse the 
preparation with lukewarm water. 
Increase the concentration to 1, 2 or 3% based on the amount of skin irritation. 
Apply during 10-30 minutes. In patients suffering from an irritative response on 
0.1%, a concentration of  
0.05% should be considered. Recommended maintenance dosage Not recommended for long-term therapy Important adverse effects (See SmPC) Erythema and burning sensation Discoloration of skin, hair, nails and clothing Blisters and necrosis Prevention/treatment of adverse effects When plaques are sharply demarcated the surrounding skin can be protected with 
zinc paste. Erythema and burning sensation can be treated with topical 
corticosteroids during 1-2 days. In case dithranol comes in contact with the eyes, 
this could cause strong irritation or iritis. Rinse the eyes thoroughly with water or prescribe an isotonic saline solution, followed by treatment with topical 
corticosteroids.  Absolute contraindications (See SmPC) Erytrodermic psoriasis Pustular psoriasis Psoriatic plaques nearby the eyes or mucosa 
Relative contraindications (See SmPC) Pregnancy (never treat >30% of the skin surface) Children Infants Important drug interactions Topical preparations with salicylic acid or 
urea can enhance the effect of dithranol.  Administration of photosensitizing agents in combination with dithranol can enhance the photosensitizing effects. Costs €1.83 – €3.92. Additional costs include 
hospitalization or outpatient treatment. Special notes A mild burning sensation indicates 
effective treatment concentration. Do not apply dithranol on the breasts in 
breastfeeding women. Patients not experienced with dithranol therapy should receive outpatient or 
hospitalized treatment.  
Conclusions of the Dutch guidelines        
The results of the evaluated studies indicate a complete remission (PASI 
reduction of 100%) in 30-70% of patients and a partial remission (PASI 
reduction of 75%) in 26-100% of patients after treatment for 5-8 weeks. 
The differences in efficacy are probably due to the lack of a standardized dithranol treatment strategy and to the differences in clinical settings: home treatment versus outpatient treatment versus hospitalized 
 
EL: 1 treatment. Skin irritation, burning sensation, erythema and intermittent brown 
discolorations are frequently reported adverse effects. Systemic adverse 
effects have never been reported.  
A2 Monastirli et al., 2002 (15); Saraswat et al., 2007 (16) 
B Gerritsen et al., 1998 (17); Prins et al., 2001 (18); Thune et al., 1992 (19); 
de Mare et al., 1988 (20); Prins et al., 2000 (21); Hutchinson et al., 2000 
(22); Mahrle et al., 1990 (23); Swinkels et al., 2002 (24); Van de Kerkhof et 
al., 2002 (25); Agrup et al., 1985 (26); de Korte et al., 2008 (27); Swinkels 
et al., 2004 (28); Van de Kerkhof et al., 2006 (29) 
C Agarwal et al., 2002 (30)  
Treatment recommendation 
Dithranol monotherapy is recommended in patients with moderate to severe psoriasis for induction therapy during hospitalization 
or outpatient treatment. 
Dithranol short-contact therapy may be an alternative treatment to phototherapy or systemic therapy in patients with moderate to 
severe psoriasis. 
In patients who are unresponsive or have a contraindication to calcipotriol, corticosteroids, photo(chemo)therapy, systemic 
therapy, and biologics, dithranol is a last resort. 
Dithranol therapy should be applied during a maximum of 4-8 weeks. Maintenance or long-term therapy is impractical and has no 
advantages.  
In treating severe chronic plaque type psoriasis, it is recommended to add phototherapy or topical preparations (Vitamin D3 
analogues, corticosteroids) to dithranol treatment because of higher efficacy. 
Corticosteroids 
Table 6: Corticosteroids Recommended initial dosage 1x daily Recommended maintenance dosage Taper when psoriasis improves, for 
example beta methasone dipropionate 1x 
daily for 3 weeks, then 1x / 2 days for 1 
week, followed by 1x / 3 days for 1 week and then ceasing medication Important adverse effects (See SmPC) Skin atrophy, teleangiectasias, secondary infection, rosacea, perioral dermatitis, corticosteroid-induced acne Prevention/treatment of adverse effects Adverse effects occurring after long-term treatment include skin atrophy and 
teleangiectasias. These adverse effects are 
hard to treat. Try to avoid these adverse effects by taking into consideration therapeutic class of drug, location of drug 
use and treatment duration. A higher therapeutic class means a higher risk of 
adverse effects. Long-term treatment with a high potent corticosteroid increases the 
risk of skin atrophy. The face, genitals, neck and flexures are especially prone to 
skin atrophy. In the flexures a secondary 
infection could occur. The face is prone to rosacea, perioral dermatitis and corticosteroid-induced acne. The scalp and the soles of hands and feet can be treated with potent corticosteroids for months or sometimes years before skin atrophy 
appears.  Absolute contraindications None Relative contraindications Rosacea, perioral dermatitis 
(See SmPC) Skin infections with bacteria (tuberculosis, lues), fungi, viruses (herpes simplex, herpes zoster, chicken-pox) Adverse effects of vaccines Important drug interactions None Costs €2.44 daily for topical corticosteroids (10 most prescribed preparations were taken into account)  
€57.24 per month for mometasone 
furoate (based on 100g / week) Special notes Most patients are afraid to use 
corticosteroids. Consequently, a detailed advice on benefits and disadvantages needs to be given to patients. During pregnancy, potent corticosteroids may induce intrauterine growth restriction when used on large surfaces for 
a long time period. During breastfeeding, do not apply corticosteroids on the breasts in order to 
avoid hospitalization of the infant. The mother must stop breastfeeding in case of long-term treatment with potent 
corticosteroids.    
Conclusions of the Dutch guidelines  After applying high potent corticosteroids (beta methasone dipropionate 
  
EL: 1 
2x daily) a substantial improvement or complete remission of skin 
lesions is seen in 46-56% of psoriasis patients  
A1 Mason et al., 2009 (12) 
A2 Papp et al., 2003 (31); Douglas et al., 2002 (32); Kaufmann et al., 2002 
(33) 
B Weston et al., 1988 (34); Bagatell, 1988 (35)     
EL: 1 
Therapy with corticosteroids of very high potency (clobetasol-17-
propionate 2x daily) has a similar efficacy in 68-89% of psoriasis patients  
A2 Gottlieb et al., 2003 (36); Lowe et al., 2005 (37) 
B Decroix et al., 2004 (38); Lebwohl et al., 2002 (39); Weston et al., 1988 
(34); Lee et al., 2009 (40) 
C Mazzotta et al., 2007 (41)     EL: 2 
Due to the small number of available studies and varying study-outcome it is unclear whether clobetasol-17-propionate is more effective as a 
cream, lotion, spray or foam.  
A2 Lowe et al., 2005 (37) 
B Lebwohl et al., 2002 (39); Lee et al., 2009 (40) 
C Mazotta et al., 2007 (41)    Owing to the small number of available studies it is unclear whether 1x daily application of topical corticosteroids is more effective than 2x daily 
EL: 2 application.  
A2 Kaufmann et al., 2002 (33)  
Treatment recommendation 
Topical corticosteroids are recommended for the treatment of mild to severe chronic plaque psoriasis. Combination therapy with 
calcipotriol, phototherapy, or systemic therapy may be prescribed, thereby reducing the total dosage of corticosteroids 
significantly. 
The class of corticosteroids prescribed depends upon the areas of skin affected. 
It is important to be aware of the occurrence of skin atrophy or teleangiectasia, especially when corticosteroids are used as long-
term therapy and are being applied in areas prone to these adverse effects. 
Owing to lack of evidence for 2x daily application of corticosteroids over 1x daily application, it is recommended to start with 1x 
daily. 
Coal tar 
Table 7: Coal tar Recommended initial dosage No recommended initial dosage; the dosage of coal tar may vary Recommended maintenance dosage It is not recommended to use coal tar for maintenance or long-term therapy Important adverse effects (See SmPC) Coal tar odor, staining,phototoxicity Prevention/treatment of adverse effects The brown-black stains in clothing and the penetrating odor are unavoidable. Patients should exercise caution with exposure to sunlight in order to avoid UV-erythema. Absolute contraindications (See SmPC) Pregnancy and breastfeeding Xeroderma pigmentosum, dysplastic nevus syndrome, basal cell nevus syndrome 
Relative contraindications (See SmPC) Intense exposure to sunlight or UV-light during treatment Prior history of skin cancer Important drug interactions There are no drug interactions reported for topical use of coal tar products Costs €3.51 daily Special notes The Goeckerman-method consists of 
application of coal tar during 1-2 hours 
followed by UVB therapy. Optimal dosage of UVB is reached when the treated skin 
does not become erythematous. In outpatient care, pix lithantracis is often used and in combination with UV-therapy shows a higher efficacy when compared to liquor carbonis detergens (LCD)/UV-light 
combination therapy.    
Conclusions of the Dutch guidelines   
EL: 3 
Coal tar monotherapy (10% LCD) seems to improve psoriatic lesions when compared to placebo, but is less effective than betamethasone 
valerate.  
B Thawornchaisit et al., 2007 (42)    EL: 2 
Coal tar (5%) is being used in clinical studies combined with 
phototherapy. When combined with UV-light a reduction of 75% in PASI score (PASI 75) was reached in 45-80% of participants after 15-20 
applications. The evidence on the additive effect of coal tar when 
combined with phototherapy is insufficient. The addition of coal tar 
might result in a faster and longer remission.  
B Bagel, 2009 (43); Belsito et al., 1982 (44) 
C Frost et al., 1979 (45)  
Treatment recommendation 
Coal tar is not the first-choice of treatment for chronic plaque psoriasis. 
Coal tar as a monotherapy is outdated. Nowadays, treatment options exist that are less hazardous and more practical. 
Only when therapeutically necessary, coal tar or pix lithanthracis may be used in combination with UVB or PUVA to treat 
recalcitrant chronic plaque psoriasis. 
Tazarotene 
Tazarotene is not available in the Netherlands and therefore not included in these guidelines. 
Vitamin D3 analogues 
Table 8: Vitamin D3 analogues Recommended initial dosage Calcipotriol: 2x daily on affected areas of the skin Calcitriol: 2x daily on affected areas 
Calcipotriol/betamethasone: 1x daily on affected areas  Recommended maintenance dosage Calcipotriol: ≤15g cream or ointment daily 
and ≤100g weekly 
Calcitriol: ≤30g ointment daily and ≤35% of body surface area Calcipotriol/betamethasone: continuous 
use during 4 weeks. Owing to lack of 
evidence on long-term continuous therapy, intermittent use of this drug is recommended Important adverse effects (See SmPC) Burning sensation, redness Overdosing: hypercalcemia, bone resorption, possibly uric acid kidney stones, or even kidney failure  Prevention/treatment of adverse effects Do not treat unaffected skin areas. In case of skin irritation, adjust frequency of 
therapy or stop briefly. Topical 
corticosteroids may reduce irritation.  Absolute contraindications None Relative contraindications (See SmPC) Pustular psoriasis Diseases involving disorders of calcium metabolism 
Treatment with medication that can cause hypercalcemia Serious kidney or liver disease Due to lack of experience, treatment during pregnancy and breastfeeding should be avoided Important drug interactions Topical salicylic acid (inactivation), avoid other topical irritating preparations Oral calcium supplementation, oral 
vitamin D3, thiazide diuretics: check serum calcium levels  Costs 120g calcipotriol cream: €37.26 
100g calcitriol ointment: €23.70 
100g Dovobet (calcipotriol/betamethasone): 
€68,- Special notes Do not apply calcipotriol before treatment with UV-light. It can diminish the effect of UV-therapy. Calcipotriol may be administered after phototherapy.  
Conclusions of the Dutch guidelines   
EL: 1 
After topical application of vitamin D3 analogues 30-50% of patients with mild to moderate chronic plaque psoriasis improved substantially or even achieved almost complete remission within several weeks  
A2 Camarasa et al., 2003 (46); Kragballe et al., 2004 (47); Zhu et al., 2007 
(48); Guenther et al., 2000 (49)     
EL: 1 
Efficacy and tolerance of vitamin D3 analogues are enhanced by combining therapy with topical corticosteroids during the first phase of 
treatment. Usage of calcipotriol/betamethasone dipropionate ointment or gel is preferred because of a higher patient compliance with 1x daily application  
A2 Papp et al., 2003 (31); Douglas et al., 2002 (32); Kaufmann et al., 2002 
(33); Tabolli et al., 2009 (50); Guenther et al., 2002 (51); Kragballe et al., 
2004 (47); Ortonne et al., 2004 (52); Kragballe et al., 2006 (53); Peeters et 
al., 2005 (54); Saraceno et al., 2007 (55)  
Treatment recommendation 
Vitamin D3 analogues are recommended as topical therapy for chronic plaque psoriasis. 
Efficacy and tolerance is higher for the combination of vitamin D analogues with corticosteroids when compared to both 
monotherapies. The combination preparation is preferred because of its 1x daily application. 
For treatment of moderate to severe chronic plaque psoriasis the use of topical vitamin D3 analogues combined with UV-therapy 
or systemic therapy is recommended. 
2.3 Phototherapy 
E.P. Prens, W.J.A. de Kort, M.B.G. Koek 
Table 9: Phototherapy Registration for psoriasis More than 50 years of experience with the oldest modality (Goeckerman) Recommended control parameters before starting treatment Regular inspection of skin every 8 to 10 treatments. Ask for UV-erythema. Recommended initial dosage Individual dosage depends on skin type; follow one treatment regimen until erythema occurs, then: 
- UVB: 70% of the minimal erythema dosage (MED) 
- Oral PUVA: 75% of the minimal phototoxic dosage (MPD) 
- Bath/cream PUVA: 30-50% of MPD Recommended maintenance dosage Increase dosage (10-30%) based on erythema  Onset of effect After 2-3 weeks Response rate UVB: 75% of patients a PASI 75 after 4-6 weeks (EL: 2) PUVA: complete clearance of skin lesions 
in 75-90% of patients (EL: 2) 
Absolute contraindications Photodermatoses/photosensitivity, skin malignancies, treatment with cyclosporine (immunosuppressant) and expected 
treatment with cyclosporine in future. 
PUVA: pregnancy or lactation. This is a 
relative contraindication for bath PUVA.   Relative contraindications Epilepsy, pregnancy or lactation (for bath PUVA), unavoidable therapy with photosensitizing agents, skin type I, dysplastic melanocytic nevi, prior history of skin cancer, poor compliance, physical or emotional inability to sustain therapy (heart failure NYHA class III-IV, claustrophobia), presence of actinic skin 
damage, children < 18 years, high cumulative number of treatments or 
dosage (for UVB: 400 treatments, this 
equals approximately 600-800 J/cm2 for 
narrow band UVB and 120-180 J/cm2 for broadband UVB therapy). For oral PUVA: High cumulative number of 
treatments (1000 J/cm2 or 150-200 treatments), prior arsenic treatment or ionizing radiation, significant liver 
damage.    Most common adverse effects ≥1/10: Erythema, itch, 
hyperpigmentation. Only for PUVA: 
nausea. Only for excimer laser: blistering. Important drug interactions Note: medication capable of inducing 
phototoxicity or photoallergy. Special notes Combination with topical preparations 
may work synergistically. PUVA should not be combined with cyclosporine. Eyes must be protected during phototherapy, as 
well as the penis and scrotum.  
Table 10: Important adverse effects of UVB and PUVA therapy 
Most frequently Erythema, itch, hyperpigmentation 
Only PUVA: nausea 
Only excimer laser: blistering 
Frequently - 
Sometimes Blistering 
Rarely Oral PUVA: squamous cell carcinoma, basal 
cell carcinoma 
Very rarely - 
 
Table 11: List of medication capable of inducing phototoxicity and photoallergy 
 Drugs inducing phototoxicity Drugs inducing photoallergy 
Tetracyclines Tiaprofenic acid 
Phenothiazine Promethazine 
Griseofulvin Chlorpromazine 
Nalidixine acid Hydrochlorothiazide 
Furosemide Quinine 
Amiodarone Para-aminobenzoic acid (PABA) ointments 
Piroxicam Desinfectants (hexachlorophene, others) 
Tiaprofenic acid  
 
Table 12: Starting dosage UVB therapy (56) 
Skin type UVB broadband (mJ/cm2) Narrow band UVB 
(mJ/cm2) 
I 20 200 
II 30 300 
III 50 500 
IV 60 600 
 
Table 13: Treatment regimen UVB phototherapy (56) 
Step 1 
Assessment of MED 
Assess after 24 hours 
Step 2 
Start of therapy 
Starting dosage According to skin type or 
70% of MED 
Step 3 
Treatment 2-3 times per 
week 
No erythema Increase by 30% 
Minimal erythema Increase by 20% 
Persisting asymptomatic 
erythema 
Do not increase dosage 
Painful erythema Interrupt treatment until 
symptoms disappear 
Step 4 
Resume treatment 
After disappearance of 
symptoms 
Lower last dosage by 50% 
Increase further by 10% 
 
Table 14: Treatment regimen localized UVB phototherapy (excimer laser or lamp) 
(57) 
 
Step 1 
Assessment of MED 
Assess after 24 hours 
Step 2 
Start of therapy 
Starting dosage 2x-4x of MED 
Step 3 
Treatment 2 times per week 
Persisting asymptomatic 
erythema 
Increase with 1x-2x MED 
Painful erythema Interrupt treatment until 
symptoms disappear 
Step 4 
Resume treatment 
After disappearance of 
symptoms 
Repeat last dosage 
 
Table 15: PUVA: most commonly used photosensitizing agents and their dosage (56, 
58) 
Modality Photosensitizing agent Dosage or concentration 
Oral PUVA 8-methoxypsoralen (8-MOP) 
5-methoxypsoralen (5-MOP) 
0.6 mg/kg 
1.2 mg/kg 
Bath PUVA 8-MOP 0.5-5.0 mg/L 
localized PUVA (emulsion 
or gel) 
8-MOP 1%-0.005% 
 
Table 16: PUVA starting dosages (57) 
Skin type Oral PUVA Bath PUVA 
8-MOP  
(J/cm2) 
5-MOP  
(J/cm2) 
1.0 mg/L 8-MOP 
(J/cm2) 
I 0.3 0.4 0.2 
II 0.5 1.0 0.3 
III 0.8 1.5 0.4 
IV 1.0 2.0 0.6 
 
Table 17: PUVA treatment regimen (57) 
Step 1 
Assessment of minimal 
phototoxic dosage 
Oral PUVA: assess after 72-96 h 
Bath PUVA: assess after 72-96 h 
Step 2 
Start of therapy 
Starting dosage Oral PUVA: According to 
skin type or 75% of MPD 
Bath PUVA: According to 
skin type or 30-50% of MPD 
Step 3 
Treatment 2x per week 
No erythema, good response Increase by 30% (max. 2 
times per week) 
Minimal erythema Do not increase 
Persisting asymptomatic 
erythema 
Do not increase 
Painful erythema Interrupt treatment until 
symptoms disappear 
Step 4 
Resume treatment 
After disappearance of 
symptoms 
Lower last dosage by 50%; 
increase further by 10%  
Conclusions of the Dutch guidelines 
UVB (broadband)     EL: 2 
About 75% of all patients treated with broadband UVB 2-3 times per week achieved at least PASI 75 response after 4-12 weeks (depending on UV schedule) and clearance was reached in most cases.  
A2 Dover et al., 1989 (59) 
B Coven et al., 1997 (60); Orfanos et al., 1979 (61); Petrozzi, 1983 (62); 
Ramsay et al., 2000 (63)  
UVB (narrow band)    EL: 2 
63% - >75% of all patients treated with narrow band UVB 2-3 times per 
week reached at least PASI 90 response within 20 weeks of treatment. Presumably higher response percentages are achieved for PASI 75. Exact data are not available since performed studies date before the “PASI-era”.  
B Arnold et al., 2001 (64); Gordon et al., 1999 (65); Markham et al, 2003 
(66); Youssef et al., 2008 (67) 
   EL: 2 
It is unclear whether phototherapy > 3 times per week results in a 
higher efficacy and faster response.  
B Coven et al., 1997 (60); Grundmann-Kollmann et al., 2004 (68); 
Leenutaphong et al., 2000 (69)  
   EL: 2 
The percentage of patients achieving PASI 75, PASI 90 or complete clearance is equally high for home UVB phototherapy as for outpatient 
phototherapy.  
A2 Koek et al., 2009 (70) 
B Cameron, 2002 (71)   
  No significant difference exists between home and outpatient 
  EL: 2 
phototherapy for total cumulative dosage of UVB at the end of treatment. 
There is also no difference between both therapies for percentage of adverse effects as for the number of adverse effects experienced at least 
once by psoriasis patients.      
A2 Koek et al., 2009 (70) 
B Cameron, 2002 (71)   
 
UVB 308 nm   EL: 2 
Individual plaques disappear completely (in 33-37%) or almost 
completely (about 70%) after treatment with the excimer laser for 8-16 
weeks.   B Hacker et al., 1992 (72); Taibjee et al., 2005 (73); Trehan et al., 2002 
(74); Goldinger et al., 2006 (75) 
C Feldman et al., 2002 (76); Han, 2008 (77) 
  
EL: 3 There is evidence the results of the excimer lamp equal the excimer laser.  
B Kollner et al., 2005 (78)  
Oral PUVA     
After 12-16 weeks, 75-90% of patients achieve near complete clearance of skin lesions when treated with oral PUVA 2-4 times per week  
A2 Yones et al., 2006 (79) 
EL: 2 B Caca-Biljanovska et al., 2002 (80); Barth et al., 1978 (81); Berg et al., 
1994 (82); Buckley et al., 1995 (83); Calzavara-Pinton et al., 1992 (84); 
Collins et al., 1992 (85); Cooper et al., 2000 (86); Diette et al., 1984 (87); 
Hanke et al., 1979 (88); Khurshid et al., 2000 (89); Kirby et al., 1999 (90); 
Park et al., 1988 (91); Parker et al., 1984 (92); Parrish et al., 1974 (93); 
Rogers et al., 1979 (94); Vella Briffa et al., 1978 (95); El-Mofty et al., 2008 
(96) 
C Henseler et al., 1981 (97)   
Bath PUVA     EL: 2 
The results of bath PUVA equal oral PUVA when treatment frequencies 
are similar.  
B Caca-Biljanovska et al., 2002 (80); Barth et al., 1978 (81); Berg et al., 
1994 (82); Buckley et al., 1995 (83); Calzavara-Pinton et al., 1992 (84); 
Collins et al., 1992 (85); Cooper et al., 2000 (86); Diette et al., 1984 (87); 
Hanke et al., 1979 (88); Khurshid et al., 2000 (89); Kirby et al., 1999 (90); 
Park et al., 1988 (91); Parker et al., 1984 (92); Parrish et al., 1974 (93); 
Rogers et al., 1979 (94); Vella Briffa et al., 1978 (95); El-Mofty et al., 2008 
(96)  
Retonoid plus PUVA / UVB   EL: 2 
There is evidence that combination therapy with PUVA / acitretin or narrow band UVB / acitretin achieves higher efficacy and is dose-sparing 
in regard to cumulative UV dosage.  
B Saurat et al., 1988 (98); Carlin et al., 2003 (99); Lauharanta et al., 1989 
(100)  Instructions for phototherapy  Prior to treatment 
• Objective assessment of psoriasis (such as PASI / BSA / PGA; arthritis) 
• Consider assessing HRQoL (e.g. DLQI, Skindex-29 or Skindex-17 or VAS) 
• Medical history and physical examination need to be directed at prior exposure, melanocytic nevi (in particular dysplastic type) and skin cancer. 
• Additional UV exposure due to recreational activities should be taken into account 
• Prescription of UVA protecting sunglasses is obligatory before commencing oral 
PUVA therapy.  During treatment 
• Physical examination 
• Objective assessment of psoriasis (such as PASI / BSA / PGA; arthritis) 
• Consider assessing HRQoL (e.g. DLQI, Skindex-29 or Skindex-17 or VAS) 
• UV dosages should be documented with precise cumulative units (J/cm2 or 
mJ/cm2) and number of treatments. 
• Ask for the occurrence of erythema on a regular basis in order to accurately determine treatment dosage 
• Physicians should report adverse effects, therapeutic response and concomitant treatments within the medical record 
• Eyes should always be protected during phototherapy with sunglasses with UV-protection as well as at least 8 hours after oral-PUVA treatment 
• Cover the genital area when skin lesions are absent. If desired, healthy skin of 
the face and other unaffected areas may be covered (possibly with adequate 
sunscreens). The area of covered skin needs to be the same during every 
treatment since a shift of 1 cm may cause burns due to unequal sensitivity of this 
area to UV light. 
• It is essential for the patient to avoid additional sun exposure and/or to use sunscreens  After treatment 
• After a treatment course, cumulative UV-dosage and number of treatments should be registered 
• Especially patients with high number of treatment episodes (200-250x PUVA) 
need to be screened routinely for skin cancer during their entire life.  
Treatment recommendation 
Phototherapy is recommended for induction therapy of moderate to severe chronic plaque psoriasis. Narrow band UVB is 
recommended as first choice; PUVA is advised in case UVB is ineffective. 
8-MOP or methoxsalen is preferred for PUVA therapy. This preparation, however, is being withdrawn from the market. The 
manufacturer states Oxsoralen (methoxsalen 10 mg capsules) can be imported by the pharmacist with a delivery time of  a week. 
Oxsoralen is not registered in the Netherlands and will not be reimbursed. The dermatologist should contact the health insurance 
of the patient to arrange a reimbursement for a non-registered drug. 
The use of excimer lasers should be limited to treatment directed at single, therapy resistant psoriatic plaques. 
UV maintenance therapy is not recommended owing to decreased efficacy after repetitive UV-exposure and increased chance of 
UV skin damage. The number of treatment courses should be limited to a maximum of 2 per year. 
UV-therapy after or during immunosuppressant drugs, especially cyclosporine, demands special attention. 
Both home and outpatient UVB phototherapy are available for the treatment of psoriasis. The dermatologist should, in 
consultation with the patient, decide which treatment setting is preferred.  
2.4 Conventional systemic therapies 
Methotrexate 
E.M.G.J. de Jong 
 
Table 18: Methotrexate Registration for psoriasis 1958 Recommended control parameters before starting treatment Hb, leucocytes and differential, thrombocytes, liver enzymes, serum creatinine, urine sediment, pregnancy test, HBV/HCV, serum albumin, PIIINP if available, X-thorax in case of suspected tuberculosis on anamnesis. Recommended initial dosage 5-10 mg weekly Recommended maintenance dosage 5-22.5 mg weekly (oral, subcutaneous or intramuscular) Onset of effect After 4-12 weeks Response rate PASI 75 in 35-73% of patients after 16 weeks Absolute contraindications (See SmPC) Severe infections, serious kidney and liver diseases, bone marrow diseases, substantial hematologic abnormalities, men and women planning to have children, pregnancy, breastfeeding, pulmonary fibrosis or poor lung function, alcohol abuse, immune deficiencies, acute 
peptic ulcer, drug abuse. Relative contraindications (See SmPC) High age, less serious kidney and liver diseases, ulcerative colitis, history of HBV or HCV, poor compliance, gastritis, diabetes, history of malignancies, heart failure, drug interactions 
Most common adverse effects (See SmPC) ≥1/10: stomatitis, dyspepsia, nausea, loose of appetite. Increase of serum 
transaminases. 
≥1/100 - ≤1/10: oral ulcers, diarrhea. 
Exanthema, erythema, itch. Headache, 
fatigue, sleepiness. Interstitial alveolitis or pneumonitis: symptoms of potentially severe damage are dry, unproductive 
cough, dyspnoe and fever. Leukopenia, 
anemia, trombopenia. Important drug interactions Trimethoprim, probenecide, retinoids, NSAIDs  Special notes Dosing once a week; overdose may lead to leukocytopenia or pancytopenia which may be life-threatening. Continue oral 
contraceptives until 3 months after 
cessation of MTX. Alcohol consumption, obesity, hepatitis and diabetes increase the risk of 
hepatotoxicity. In geriatric patients a 
lower dose of MTX is usually prescribed and kidney function should be monitored 
on a regular basis.  
Conclusions of the Dutch guidelines   Methotrexate is effective for the treatment of plaque psoriasis in adults. After 16 weeks, in 35-73% of psoriasis patients a PASI 75 response was 
EL: 1 reached on 15-22.5mg methotrexate weekly.  
A2 Flystrom et al., 2008 (101); Ranjan et al., 2007 (102); Saurat et al., 
2008 (103); Heydendael et al., 2003 (104); Akhyani et al., 2010 (105)  
Table 19: Important adverse effects of MTX 
Most frequently Stomatitis, dyspepsia, nausea, loose of 
appetite. Increase of serum transaminases.  
Hair loss. 
Frequently Oral ulcers, diarrhea. Leukopenia, anemia, 
trombopenia. 
Sometimes Fever, shivers, depression, infections 
Rarely Nephrotoxicity, liver fibrosis / cirrhosis 
Very rarely MTX alveolitis or pneumonitis.  
Table 20: List of medication and drug interactions 
Medicine Type of drug interaction Colchicin, cyclosporine, NSAIDs, penicillin, probenecide, salicylic acids, sulfonamides Reduced renal clearance of MTX Chloramphenicol, co-trimoxazol, cytostatics, ethanol, NSAIDs, sulfonamides Increased risk of bone marrow and gastrointestinal toxicity Barbiturates, co-trimoxazol, phenytoin, probenecide, NSAIDs, sulfonamides Interaction with plasma protein binding Ethanol, leflunomide, retinoids, tetracyclines Increased risk of hepatotoxicity   
Instructions for MTX use  Prior to treatment 
• Medical history and physical examination 
• Assessing disease severity, preferably with PASI or PGA 
• Consider assessing HRQoL (e.g. DLQI, Skindex-29 or Skindex-17 or VAS) 
• Laboratory controls (Table 21) 
• Start contraceptives in fertile women (start after menstruation), contraceptive measures in men 
• In case liver function screening shows abnormalities, refer to specialist for further evaluation 
• Influenza vaccination is recommended 
• X-thorax in case of suspected tuberculosis on anamnesis.  During treatment 
• Objective assessment of disease severity using PASI or PGA 
• Consider assessing HRQoL (e.g. DLQI, Skindex-29 or Skindex-17 or VAS) 
• Medical history 
• Physical examination 
• Laboratory controls (Table 21) 
• Contraceptive measures in fertile women and men 
• Administer folic acid once weekly at least 24 hours after MTX* 
• Intake of MTX with milk reduces the absorption of MTX  After treatment 
• Women should not become pregnant and men should not conceive children 
during MTX treatment and 3 months thereafter. 
 
* Folic acid dosage varies in the literature between 1 to 5mg daily and 1 to 2.5-10mg 
weekly (Prey, 2009). 
The working group of these guidelines holds the opinion that dosage of folic acid should be 
flexible with 1mg daily (except for the day of MTX intake) to 5-10mg once weekly 
administered at least 24 hours after MTX intake. The guidelines of the Dutch Society of 
Rheumatology advice to prescribe at least 5mg of folic acid weekly, at least 24 hours after 
MTX intake. It is recommended to double this dosage in case MTX dosage becomes ≥15mg 
weekly.  
Table 21: Laboratory controls  
Parameter* Prior to treatment After the first 
week of treatment 
During the first 
two months 1x 
every 2 weeks, 
thereafter every 2-
3 months. Hb, leucocytes and differential, thrombocytes, erythrocytes 
X X X 
Liver enzymes 
(ALAT, AP, yGT) X X X Serum creatinine X X X Urine sediment X X X Pregnancy test X   HBV/HCV X   Serum albumin** X X X 
PIIINP if available X Every 3 months*** 
Further testing may be required based on patient’s status, risk and exposures.  
* Decrease MTX dosage or stop MTX in case leukocytes are <3.0, neutrophils <1.0, 
thrombocytes<100 or liver enzymes >2x the upper limit normal range 
** In certain patients (e.g. suspicion of hypoalbuminemia or patients using other medication with strong serum albumin binding properties) 
*** Liver biopsy should be considered in selected patients, e.g. patients with a 
continuous elevated PIIINP level (>4.2 mcg/l in at least 3 samples during a 12 month time period)  
Table 22: PIIINP (amino-terminal propeptide of type III pro-collagen) cut-off levels 
and clinical guidance 
PIIINP (amino-terminal propeptide of type III pro-collagen) for psoriasis 
Reference range: 1.7 – 4.2 mcg/L. First serum sample before starting MTX, thereafter 1x every 3 months. 
Confounding factors: arthritis, age <18 years, scleroderma, myeloproliferative disorders, malignancies (breast carcinoma, hepatocellular carcinoma, ovarian carcinoma), recent myocardial infarction. A gastroenterologist should be consulted (after exclusion of confounding factors) when: 
PIIINP value is >8.0 mcg/L prior to starting MTX 
PIIINP value is >4.2 mcg/L in at least 3 samples during a 12 month time period 
PIIINP value is >8.0 mcg/L in at least 2 consecutive samples 
PIIINP value is >10 mcg/L in 1 sample. In this case, provisionally stop MTX.   
Table 23: Liver biopsy: Roenigk classification of liver damage and its therapeutic 
consequences 
Histological classification: 
 Grade I: Normal   Grade II: Changes, no fibrosis   Grade IIIA: Mild fibrosis   Grade IIIB: Moderate to severe fibrosis   Grade IV: Cirrhosis    
Therapeutic consequences:  
Grade I and II: MTX may be continued   
Grade IIIA: MTX may be continued, but liver biopsy needs to be repeated after 6 months   
Grade IIIB and IV: stop MTX  
Table 24: Folic acid dosage in case of MTX overdose 
Serum MTX (M) Parenteral administration of folic acid 
once every 6 hours (dosage in mg) 
5 x 10-7 20 
1 x 10-6 100 
2 x 10-6 200 
>2 x 10-6 Increase dosage proportionally   
Treatment recommendation 
Treatment with methotrexate (15-22.5 mg/week) is effective for plaque psoriasis and induces a reduction of PASI score of at least 
75% (PASI75) in 35-73% of patients after 16 weeks of treatment. Owing to its slow onset of effect, methotrexate is less suitable 
for short induction treatment than for long-term therapy.  
It is recommended to supply folic acid to reduce the risk of hepatic adverse effects. The dosage may vary from 1mg daily (except 
for the first day of MTX intake) to 5-10mg once weekly, with a time interval between MTX intake and start of folic acid of at 
least 24 hours.  
Before starting MTX therapy and every 3 months thereafter, it is recommended to monitor for liver damage by measuring liver 
enzymes and PIIINP. 
PIIINP measurement should be available for all Dutch dermatologists. Values should be given preferably with interpretation of the 
results and advice. Several hospitals should offer the possibility of PIIINP measurement. Currently, PIIINP measurement is 
available in the University Medical Centre Nijmegen and VU Medical Centre Amsterdam. 
Because of the occurrence of overdosing of MTX (e.g. prescribed once daily instead of once weekly) with sometimes lethal 
consequences it is recommended to prescribe the recipe for MTX carefully. It must be clearly stated that dosage is once weekly. It 
is strongly advised by The Dutch health inspection that physicians should state the indication of MTX on the recipe. Patients 
should be informed about the once weekly treatment regimen. 
Owing to the possible mutagenic effects of MTX fertile men and woman should be strongly advised to use reliable contraceptives. 
Cyclosporine 
Ph.I. Spuls, M. de Groot 
Table 25: Cyclosporine Registration for psoriasis 1993 Recommended control parameters before starting treatment Hb, leucocytes and differential, thrombocytes, serum creatinine, urea, uric 
acid, liver enzymes (ASAT, ALAT), bilirubin, 
alkaline phosphatase, yGT, LDH, albumin, sodium, potassium, magnesium only in case of muscle cramps, urine sediment, cholesterol / triglycerides, pregnancy test, 
blood pressure. Recommended initial dosage 2.5-3 (max. 5) mg/kg per day for 4-6 weeks. 
When skin does not improves, increase to 5 mg/kg/day Recommended maintenance dosage Lower dosage every two weeks until a 
maintenance dosage of 0.5-3 mg/kg/day is 
reached, divided into 2 doses. Increase 
dosage in case of recurrence of psoriasis. 
Maximal total duration of therapy: 2 years. (EDF guidelines, 2009) Onset of effect After 4 weeks Response rate The response is dose-dependent. After 8-16 
weeks of treatment with 3 mg/kg/day, PASI 
75 is reached in approximately 50% of 
patients after 8 weeks. Absolute contraindications (See SmPC) History of serious adverse effects on or hypersensitivity to cyclosporine, poor kidney function, severe liver disease, severe hypertension, serious infections, malignancy (current or past, especially hematologic or cutaneous malignancies except for basal cell carcinoma), concurrent PUVA treatment, contra-indicated concomitant medication, 
vaccination with live vaccines, gout.  Relative contraindications (See SmPC) Prior potential carcinogenic treatment (arsenic, PUVA > 1000 J/cm2 or 150-200 applications), prior long-term MTX use, psoriasis induced by serious infection or medication (beta blocker, lithium, antimalarial medication), liver function disorders, hyperuricemia, hyperkalemia, epilepsy/convulsions, inadequate efficacy in the past, simultaneous treatment with nephrotoxic drugs, polypharmacy (e.g., HIV patients), simultaneous use of other systemic immunosuppressive drugs, concurrent phototherapy, simultaneous use of systemic retinoids or retinoid therapy 4 weeks prior to commencing cyclosporine treatment, drug or alcohol related diseases or substance abuse or alcohol abuses, pregnancy/breastfeeding, current treatment with ricinus oil 
preparations. Most common adverse effects (See SmPC) ≥1/100 - <1/10: kidney insufficiency (dose-dependent), irreversible kidney damage (long-term therapy), hypertension, gingival hyperplasia, reversible gastrointestinal complaints (dose-dependent), tremor, fatigue, headache, burning sensation of hands and feet, reversible hyperlipidemia 
(especially in combination with systemic corticosteroids), hypertrichosis, abnormal 
liver function tests. Important drug interactions Many different drug interactions: see SmPC text and Dutch guidelines (http://www.huidarts.info/documents/uploaded_file.aspx?id=579) Special notes Increased risk of lymphoproliferative 
diseases in transplant patients. Increased risk of squamous cell carcinoma in psoriasis patients after photo(chemo)therapy (106). 
 
Special warnings: - The capsules contain a small amount of 
alcohol (intake of 100 mg capsules equals 0.1 g alcohol) - There is a potential risk of drug interactions, especially with statins 
(increased risk of myopathy). - When idiopathic intracranial hypertension is diagnosed, cyclosporine should be stopped 
in order to avoid permanent decline in vision. - Yearly assessment of GFR is the most accurate method in order to assess kidney tolerance to cyclosporine in long-term 
therapy. -  Supplementation with magnesium seems to protect against loss of kidney function as well 
as chronic cyclosporine nephrotoxicity by adapting the activity of nitrogen monoxide 
synthase (107).  
Special attention to switching therapies: - Switching from cyclosporine to other cyclosporine (other manufacturer): be aware of differences in biological availability and if 
necessary adjust dosage. - Cyclosporine may be used after systemic retinoid therapy, that is 4 weeks after 
cessation of retinoid treatment. - Fumaric acid esters and cyclosporine are 
usually not combined. - In case of insufficient response to cyclosporine a switch to a biological agent 
may be considered. A period of simultaneous usage of both biological agent and cyclosporine may be considered in spite of synergistic toxicity (infections, 
hepatotoxicity).   
Conclusions of the Dutch guidelines     
Cyclosporine is effective for the treatment of moderate to severe chronic 
plaque psoriasis in adults. PASI 75 was reached in 20-71% of psoriasis 
patients on 2.5-5 mg/kg/day cyclosporine at week 8-16 and PASI 90 was reached in 33% of patients on 3-5 mg/kg/day at week 16. Most included 
EL: 1 studies showed a clinical relevant response 4-6 weeks after commencing 
therapy.  
A2 Heydendael et al., 2003 (104); Gisondi et al., 2008 (108); Koo, 1998 
(109); Ellis et al., 1991 (110)  
Table 26: Important adverse effects of cyclosporine 
Frequently Kidney insufficiency (dose-dependent), irreversible kidney damage (long-term therapy), hypertension, gingival hyperplasia, reversible gastrointestinal complaints (dose-dependent), tremor, fatigue, headache, burning sensation of hands and feet, reversible hyperlipidemia (especially in combination with systemic corticosteroids), hypertrichosis, abnormal 
liver function tests. 
Sometimes Convulsion, gastrointestinal ulcers, weight gain, hyperglycemia, hyperuricemia, hyperkalemia, hypomagnesemia, acne, 
anemia.  
Rarely Ischemic heart disease, pancreatitis, polyneuropathy (motoric), decreased eyesight, decreased hearing, central ataxia, myopathy, erythema, itch, leucopenia, 
thrombocytopenia. 
Very rarely Microangiopathic hemolytic anemia, 
hemolytic uremic syndrome, colitis (isolated cases), papillary oedema (isolated cases), idiopathic intracranial 
hypertension (isolated cases).  Instructions for cyclosporine use  Prior to treatment 
• Objective assessment of psoriasis (such as PASI / BSA / PGA; arthritis) 
• Consider assessing HRQoL (e.g. DLQI, Skindex-29 or Skindex-17 or VAS) 
• Medical history and physical examination need to be directed at prior diseases 
and current comorbidity (e.g., serious infections, (skin) malignancies, kidney and 
liver diseases). Also, possible drug-interactions involving current concomitant 
medication and contraindications should be ruled out.  
• Measure blood pressure at two separate consultations if first measurement was 
elevated.  
• Laboratory controls (Table 27) 
• Reliable contraceptive (note: contraceptives with progesterone become less effective) 
• Gynecological screenings should be performed on a regular basis according to the 
Dutch national guidelines on cervix carcinoma. 
• Inform patients about vaccination (especially live attenuated vaccines), patient’s susceptibility to infections (take infections serious, apply adequate medical assistance), drug interactions (inform other treating physicians on therapy), avoidance of excessive sun exposure, advice the use of sunscreens.   During treatment 
• Objective assessment of disease severity (such as PASI / BSA / PGA; arthritis) 
• Consider assessing HRQoL (e.g. DLQI, Skindex-29 or Skindex-17 or VAS) 
• Physical examination should include examination of skin and mucous membranes for formation of skin malignancies (also inspect for increase of hair growth on the body, gingival changes), signs of infections, gastrointestinal or 
neurological symptoms. 
• Repeat the advice on avoidance of excessive sun exposure and using sunscreens 
• Check concomitant medication 
• Measure blood pressure 
• Laboratory controls (Table 27) 
• If creatinine levels are increased or if patient is treated > 1 year, assess the 
creatinine clearance (or 51 Cr-labeled EDTA clearance if available) 
• Routine assessment of cyclosporine serum levels is not recommended (see Dutch 
S3-guidelines for details: 
http://www.huidarts.info/documents/uploaded_file.aspx?id=579) 
• Reliable contraceptive  After treatment 
• After cessation of cyclosporine, the dermatologist needs to inspect the patient for the formation of skin malignancies, especially in cases in which extensive UV-therapy or UV-exposure preceded cyclosporine treatment.  
Table 27: Laboratory controls 
Parameter Prior to 
treatment Treatment period (in weeks)   2 4 8 12 16 Blood count* X X X X X X 
Liver values** X X X X X X Electrolytes*** X X X X X X Serum creatinine X X X X X X Urine sediment X  X   X Urea and uric acid X  X X X X Pregnancy test (urine) X      Cholesterol, triglycerides X****   X  X Magnesium***** X   X  X 
* Leucocytes, thrombocytes, erythrocytes 
** Transaminase, AP, yGT, bilirubin, LDH, albumin 
*** Sodium, potassium 
**** Recommended 2 weeks prior to treatment and on the first day of treatment (fasting). 
***** Only if indicated (e.g., muscle cramps). Also consider CPK. 
Treatment recommendation 
3-5 mg/kg/day Cyclosporine is recommended for induction therapy in patients with moderate to severe plaque psoriasis. Because 
of its fast onset of action, cyclosporine is appropriate for short-term induction therapy or crisis intervention.  
Cyclosporine may be used to induce remission in adults with moderate to severe chronic plaque psoriasis who are undertreated 
with topical preparations or phototherapy. 
Cyclosporine may be used for long-term treatment (up to 2 years) in individual cases, but patients must be screened intensively for 
signs of toxicity, especially for decrease in kidney function and the development of hypertension. 
Retinoids 
M. te Booij, P.C.M. van de Kerkhof, M.C. Pasch 
Table 28: Retinoids Registration for psoriasis 1992 (Germany) 
Recommended control parameters before starting treatment Hb, Hct, leukocytes, trombocytes, liver enzymes (ASAT, ALAT), AP, yGT, serum creatinine, pregnancy test, blood glucose (fasting), triglycerides/cholesterol/HDL, perform X-ray examination of bones when 
symptoms exist (Ormerod, 2010) Recommended initial dosage 0.3-0.5 mg/kg/day during 4 weeks, 
followed by 0.5-0.8 mg/kg/day Recommended maintenance dosage Individual dosage depends on response and tolerance Onset of effect After 4-8 weeks Response rate Varies strongly and is dose-dependent, unambiguous conclusions cannot be 
stated, 25-75% reach partial remission 
(PASI 75) (30-40 mg/day) (Level of 
evidence: 3) Absolute contraindications (See SmPC) Kidney and liver damage, fertile women planning to have children, concomitant medication interacting with retinoids, hepatotoxic concomitant medication, pregnancy, breast-feeding, alcohol abuse, 
blood donation. Relative contraindications (See SmPC) Alcohol use (111), diabetes mellitus, use of contact lenses, children, history of pancreatitis, hyperlipidemia (especially hypertrygliceridemia) and hyperlipidemia treated with medication, atheroclerosis.   
Most common adverse effects (See SmPC) ≥ 1/10: vitamin A toxicity (cheilitis, xerosis, epistaxis, alopecia, increased skin fragility) 
≥ 1/100 to < 1/10: conjunctivitis (be aware of contact lenses), hair loss, 
photosensitivity, hyperlipidemia. Important drug interactions Phenytoin, tetracycline, methotrexate, alcohol, minipill, lipid lowering drugs (see also table 30). Special notes Continue contraceptive use at least 2 years after cessation of  medication in fertile women  
Conclusions of the Dutch guidelines     EL: 2 
Acitretin is effective in the treatment of adult patients with moderate to 
severe plaque psoriasis. 11% (A2) – 50% (B) of psoriasis patients 
treated with 0.5 mg/kg/day acitretin reached PASI 90 response at week 
8-12 and 25-41% of patients reached PASI 75 at week 8-12 when treated 
with 10-75 mg/day acitretin.  
A2 Kragballe et al., 1989 (112) 
B Gupta et al., 1998 (113); van de Kerkhof et al., 1998 (114)  
Table 29: Important adverse effects of retinoids 
Most frequently Vitamin A toxicity (xerosis, cheilitis) 
Frequently Conjunctivitis (be aware of contact lenses), hair loss, photosensitivity, 
hyperlipidemia. 
Sometimes Muscular, joint and bone pain, retinoid-induced dermatitis 
Rarely Gastrointestinal complaints, hepatitis, 
jaundice. Bone changes with long-term 
use. 
Very rarely Idiopathic intracranial hypertension, decreased color vision, nyctalopia   
Table 30: List of medication and drug interactions 
Medicine Type of drug interaction 
Tetracycline Induction of idiopathic intracranial hypertension  Phenytoin Shift of plasma proteins Vitamin A Increasing the effect of retinoids Methotrexate Hepatotoxicity Low dosage of pill with progesterone Insufficient contraceptive effect Lipid lowering drugs Increased risk of myotoxicity Antifungal imidazoles Hepatotoxicity  Instructions for retinoid use  Prior to treatment 
• Medical history and physical examination should be directed at muscle and 
skeletal problems. When patients experience symptoms supplementary imaging 
studies may be performed. 
• Consider assessing HRQoL (e.g. DLQI, Skindex-29 or Skindex-17 or VAS) 
• Exclude the possibility of pregnancy/lactation: patients have to be extensively informed about the teratogenic risk of the drug, the necessity of long-term effective contraceptives up to 2 years after cessation of acitretin therapy and the possible consequences of pregnancy during retinoid use: this must be well 
documented by the physician.  
• Patients should be informed about the specific risks of excessive alcohol 
consumption. Inform female patients about the increased conversion of acitretin 
into etretinate.  
• Direct the patient that blood donation is not allowed during and until 1 year after treatment 
• Laboratory controls (Table 31)  During treatment 
• Capsules should be taken during a meal or with milk 
• Consider assessing HRQoL (e.g. DLQI, Skindex-29 or Skindex-17 or VAS) 
• It is required to avoid pregnancy. Treatment is started at the second or third day 
of the menstruation cycle after adequate contraceptive use for at least 1 month 
prior to treatment. It is recommended to use 2 contraceptives simultaneously 
(e.g., condom + pill; IUD/NuvaRing + pill; note: avoid the use of preparations with low dose progesterone / mini-pill) during treatment and up to 2 years after 
cessation of treatment.  
• Avoid excessive usage of alcohol 
• Ask patient about symptoms of the back and joints. When patients experience 
symptoms supplementary imaging studies may be performed. 
• Laboratory controls (Table 31)  After treatment 
• Reliable contraceptives in fertile women up to 2 years after cessation of treatment 
• It is recommended to use 2 contraceptives simultaneously, as stated above 
• Patients are not allowed to be blood donors for 1 year after cessation of treatment  
Table 31: Laboratory controls 
Parameter Prior to 
treatment Treatment period (in weeks)   1 2 4 8 12 16 Blood count* X    X  X Liver values** X  X X X  X Serum creatinine X       Pregnancy test (urine) X Monthly during treatment Blood glucose (fasting) 
X       
Tryglicerides, cholesterol, HDL 
X   X   X 
Further testing may be required based on clinical symptoms, risk and exposures 
* Hb, Hct, leukocytes, thrombocytes 
** ASAT, ALAT, AP, yGT 
Treatment recommendation 
0.5mg/kg/day acitretin is recommended for induction therapy of moderate to severe psoriasis. 
When induction therapy is considered to be effective after 10 – 16 weeks, maintenance therapy may be considered using the 
lowest effective dosage. 
When conventional systemic therapies are indicated, acitretin is not recommended as first-choice monotherapy.   
Fertile women planning to have children should not be treated with acitretin owing to its teratogenic properties. 
Fumaric acid esters 
H.B. Thio, E.P. Prens 
Table 32: Fumaric acid esters Registration for psoriasis 1994 (Germany), not registered in the Netherlands Recommended control parameters before starting treatment Complete blood count, liver enzymes serum creatinine, urine sediment, 
pregnancy test. Recommended initial dosage See dosing scheme (Table 33) Recommended maintenance dosage Determine individually Onset of effect After 6 weeks Response rate 18-46% PASI 90 after 16 weeks of treatment 
50-70% PASI 75 after 16 weeks of treatment Absolute contraindications (See SmPC) Severe liver and/or kidney diseases, gastrointestinal diseases, hematological malignancies, pregnancy or breastfeeding Relative contraindications (See SmPC) Hematological diseases (deviation in blood count), simultaneous usage of drugs that have the potential to induce nephrotoxicity 
Most common adverse effects (See SmPC) ≥ 1/10: diarrhea, flushing ≥ 1/100 to < 1/10: cramps, flatulence, lymphocytopenia, eosinophilia Important drug interactions No known drug interactions Special notes Especially applicable for long-term therapy   
Conclusions of the Dutch guidelines     EL: 2 
Fumaric acid esters result in almost complete remission in 24% 
(weighted average, 18-46%) of patients after 16 weeks of treatment. 
Partial remission (PASI 75) is seen in 50-70% of patients after 16 weeks 
of treatment. Good efficacy was reached in both short-term and long-
term (maintenance) therapy.  
A2 Altmeyer et al., 1994 (115); Gollnick et al., 2002 (116) 
B Nugteren-Huying et al., 1990 (117); Kolbach et al., 1992 (118); Nieboer 
et al., 1990 (119) 
C Altmeyer et al., 1996 (120); Bayard et al., 1987 (121); Litjens et al., 2003 
(122); Carboni et al., 2004 (123); Mrowietz et al., 1999 (124)  
Table 33: Dosing scheme for dimethyl fumarate   
Time 
Dimethyl fumarate 30 mg  Number of tablets / day 
Dimethyl fumarate 120 mg  Number of tablets / day 
Week 1 0-0-1 - Week 2 1-0-1 - 
Week 3 1-1-1 - 
Week 4 - 0-0-1 
Week 5 - 1-0-1 
Week 6 - 1-1-1 
Week 7 - 1-1-2  Evaluate clinical response: 
In case PASI response ≥ 
50% 
In case PASI response ≤ 
50% 
 
Maintain 1-1-2  Proceed to 2-1-2 (week 8) 
Week 8 - 2-1-2 
Week 9 - 2-2-2  
Table 34: Important adverse effects of fumarates 
Most frequently Diarrhea, flushing 
Frequently Cramps, flatulence, lymphocytopenia, eosinophilia 
Sometimes Nausea, dizziness, headache, fatigue, proteinuria, increase of creatinine levels, increase of liver enzymes levels 
Rarely Isolated increase of ALAT or bilirubin  Instructions for use of fumaric acid esters  Prior to treatment 
• Objective assessment of psoriasis (such as PASI / BSA / PGA; arthritis) 
• Consider assessing HRQoL (e.g. DLQI, Skindex-29 or Skindex-17 or VAS) 
• Medical history and physical examination 
• Laboratory controls (Table 35)  During treatment 
• Objective assessment of psoriasis (such as PASI / BSA / PGA; arthritis) 
• Consider assessing HRQoL (e.g. DLQI, Skindex-29 or Skindex-17 or VAS) 
• Physical examination 
• Laboratory controls (Table 35)  After treatment 
• None  
Table 35: Laboratory controls 
Parameter Prior to 
treatment Treatment period (months) 3rd month, thereafter once every 3 months, 
followed by once 
every 6 months after 1 
year of treatment   1 2  
Total blood count (leucocytes, differential) 
X X X X 
Liver enzymes 
(yGT, ALAT, 
ASAT) 
X X X X 
Serum creatinine X X X X 
Urea X X X X Cholesterol X X X X Urine sediment X X X X Urine protein X X X X Pregnancy test (urine) X     
Treatment recommendation 
Fumaric acid esters are recommended according to dosing scheme for induction therapy of patients with moderate to severe 
chronic plaque psoriasis 
When induction therapy is considered to be effective after 10 – 16 weeks, maintenance therapy may be considered using the 
lowest effective dosage. 
Fumaric acid esters may be considered as first-choice systemic monotherapy. 
2.5 Biologics 
Biologics in general 
T.E.C. Nijsten 
Therapeutic response 
The primary outcome in the evaluation for therapeutic response of psoriatic drugs remains the improvement of clinical disease 
severity (PASI 75 or PGA mild to absent), but patient-reported outcome measures (e.g. patient preference, treatment satisfaction 
and/or improvement in quality of life) are increasingly important [125]. The momentum of treatment evaluation is preferentially 
24 weeks (initiation period), but for some treatments this may be at 16 weeks (e.g. adalimumab and infliximab). 
When therapeutic response is considered suboptimal (PASI 75%-50% and PASI 50%) or insufficient by the patient several 
alternatives are possible: increase dosage or dosage frequency, combination therapy (for example adding topical therapies, UV-
therapy and/or methotrexate or acitretin) or switch to another (biologic) therapy.  
Transition 
Clinical experience shows that switching between biologics of the same or different class may be effective in patients not 
responding to an anti-TNF alpha agent. Insufficient therapeutic response to a TNF-alpha antagonist does not imply ineffectiveness 
of the other biologics inhibiting TNF alpha. Of course patients can be switched to ustekinumab, a biologic with a completely 
different mode of action. The same applies vice versa. The evidence of the effectiveness of switching between biologics is derived 
from small observational studies and (retrospective) case series [126, 127]. 
Hepatitis / HIV 
Owing to the immunosuppressive properties of biologics it is advised to exclude chronic and active infections with HBV, HCV, 
and HIV in psoriasis patients before commencing biologic therapy. The following recommendations are based upon small case-
series since solid clinical studies are lacking. 
In chronic carriers of hepatitis B (HBsAg positive), there is a risk of reactivation of the virus (with the complication of acute liver 
failure). Therefore, these patients should not be treated with biologics, except when simultaneously treated with nucleoside 
analogues and guided by a gastrointestinal (GI) specialist. 
In HCV infected psoriasis patients, biologic therapy may be started with adequate monitoring and in consultation with a GI 
specialist. HCV, in contrast to HBV, lacks the possibility of integrating into the DNA of hepatocytes and thus the risk of HCV 
flares is absent.  
In HIV infected psoriasis patients, anti-TNF alpha therapy may be prescribed when the infection is controlled by HAART therapy. 
Additional controls are required given the possibility of drug interactions. Naturally, the patient should be treated in close 
consultation with the treating physician. Such experiences are lacking for ustekinumab therapy.  
Malignancies 
The risk of the occurrence of malignancies (especially lymphomas and cutaneous squamous cell carcinomas) related to 
immunosuppressive agents such as biologics remains an issue of concern. Psoriasis patients may already have an increased risk of 
developing skin cancer because of prior UV-phototherapy (especially PUVA), which is further increased after initiation of 
immunosuppressive drugs (e.g., cyclosporine and biologics) in patients with a history of high levels of UV exposure [128, 129, 
130, 131]. Therefore, all patients and especially those with a prior history of intensive immunosuppressive therapy or PUVA 
therapy should be examined for melanoma and non-melanoma skin cancer prior to and during anti-TNF alpha treatment. 
Spontaneous reporting registries have identified an increased risk of hepatosplenic T-cell carcinoma, which is often lethal, in 
patients using infliximab and adalimumab. 
Long-term effects of ustekinumab are likely to be comparable to other biologics but relatively little is known because relatively 
few patients have used these drugs for a long period compared to the TNF antagonists. In clinical trials, some patients developed a 
basal cell carcinoma during ustekinumab treatment. Hence, screening for malignancies by physical examination (mainly the skin) 
and a complete blood sample is being advised before commencing therapy with ustekinumab. 
In order to optimally assess the long-term safety and stimulating effects on the carcinogenesis of biologics well-designed and 
independent post-marketing studies (phase IV) are needed. Until now, few studies on the long-term safety are published [132, 
133]. Large (inter)national prospective registers (e.g. PsoNet) of patients on biologic therapy may be helpful in detecting and 
estimating the risks associated with the use of biologics. Physicians are therefore encouraged to participate in patient registers (if 
available). 
Demyelinating diseases 
TNF-alpha antagonists are associated with the development or worsening of demyelinating diseases and multiple sclerosis. 
Cardiovascular diseases 
TNF-alpha antagonists are able to worsen (pre-existing) heart failure and should not be prescribed to psoriasis patients with severe 
congestive heart failure (NYHA class III or IV). Patients with a mild form of heart failure being administered an anti-TNF alpha 
agent for psoriasis should be carefully monitored and also guided by a cardiologist. 
Data from a meta-analysis seem to implicate a short-term increased risk for myocardial infarction, cerebrovascular accident, and 
cardiovascular mortality for ustekinumab (and briakinumab) [134]. Further studies are required, but this seems to be a specific 
complication of this class of biologics.    
Infections 
TNF-alpha antagonists increase the risk of infection including tuberculosis (TB). Reactivation of (latent) TB seems to occur more 
often with infliximab and adalimumab therapy compared to etanercept. It is mandatory to screen for latent TB before commencing 
therapy with a biologic (see chapter: screening for tuberculosis). Other infections include upper and lower respiratory tract 
infections, urinary tract infections and skin infections [135]. 
Pregnancy 
The experience with biologics just before and during pregnancy is too limited to claim safety of its (continuous) use. 
Fertility 
It is uncertain whether biologics reduce spermatogenesis [136, 137, 138]. No data has been published about the influence of TNF-
alpha blockade on female fertility.  
Transplacental passage 
Biologics (adalimumab, infliximab and etanercept) may pass the placental barrier during the first, second, and especially third 
trimester [139]. 
Lactation 
Mothers wishing to breastfeed their child have to be informed about the uncertainty of the influence of biologics on children and 
need to be advised about alternatives for lactation. 
Biologics and antibody formation 
L.L.A. Lecluse 
As with other foreign proteins, treatment with biologics may cause antibody formation.  
Neutralizing antibodies have been shown against adalimumab, infliximab, and ustekinumab, but not against etanercept [132, 140, 
141]. For adalimumab and infliximab routine screening can be done. Antibodies against ustekinumab are tested in an experimental 
setting at this moment.  
When to check for antibodies 
Assessment of antibody titer may be indicated in patients treated with adalimumab or infliximab when: 
I There is a significant decrease in effectiveness of the agent involved  
II The psoriasis is recalcitrant to improvement since commencing therapy 
III An infusion reaction occurs (only with infliximab)  
How to interpret and act on antibody titers 
Situation I 
The effectiveness of the biologic declines, the antibody titer is low, and serum concentration value of the biologic is decreased. 
The biologic may be continued, but dosing frequency or dosage of this drug may be increased to reduce antibody formation. Costs 
of treatment will rise. 
 
Situation II 
There is no clinical sign of effectiveness of the biological agent, the antibody titer shows high levels of antibodies, and the 
biologic serum concentration is undetectable. 
The biologic should not be continued because the antibodies are neutralizing the biological agent. Consider switching to a biologic 
of a similar or different therapeutic class. 
 Situation III 
There is no clinical sign of effectiveness of the biological agent, the antibody titer shows no antibodies, and the biologic serum 
concentration is within normal range. 
The patient does not respond to therapy. Consider switching to a biologic of a different therapeutic class. 
Screening for tuberculosis 
A.C.Q. de Vries, H. van Deutekom, T.E.C. Nijsten, Ph.I. Spuls 
Table 36: Plan of action for tuberculosis screening 
Diagnostic approach to TB, regardless of BCG vaccination status, prior to and during follow-ups of treatment with biologic agents. Physicians should be alert to the 
occurrence of TB during treatment and 6 months thereafter [142]. During treatment 
yearly screening is advised for latent TB. Medical history, Mantoux and IGRA are 
recommended. To limit the influence of immunosuppressive drugs on Mantoux and IGRA a treatment-free interval may be introduced a week before screening.  Medical history:  
- Symptoms indicating possible TB 
- Prior history of TB, possibly treated sufficiently 
- Exposition to TB 
- Originating from or recent long stay in an epidemic area 
- Risk patient 
- BCG vaccination status  Physical examination, consider: 
- Auscultation of lungs when symptomatic (non-specific for TB diagnosis) 
- Scar (left) upper arm (possible BCG vaccination)  Chest X-ray 
- Signs of active or past TB? 
 Consult pulmonologist in case of abnormalities  Mantoux 
- ≥ 5mm induration  positive  consider latent TB infection (LTBI) or active TB 
infection (TBI)  consult pulmonologist 
- < 5mm induration: - age < 65 years: draw blood for IGRA test - age ≥ 65 years: repeat Mantoux after 2 weeks   • ≥ 5mm induration  positive  consult pulmonologist   • < 5mm induration  draw blood for IGRA test  
IGRA (Altena, 2010)  
Mantoux IGRA Diagnosis Management 
< 5mm Negative Depending on medical history - Start a biologic agent when medical history (symptoms, prior history, exposition, origin, recent stay, risk patient) reveals no signs of 
or risk to TB - In case medical history reveals signs of or risk to 
TB, consult a pulmonologist for further diagnostics and treatment - HIV-infected patients with a low CD-4 count could still have a TB infection    
≥ 5mm < 10mm Negative Strongly consider 
LTBI and active TB Consult pulmonologist for further diagnostics and treatment 
> 10 mm Negative LTBI Consult pulmonologist for further diagnostics and treatment Every value QFT-G 
0.2-0.35 U/ml Strongly consider LTBI Consult pulmonologist for treatment Every value Positive 
(QFT-G > 0.35 U/ml) 
LTBI Consult pulmonologist for treatment  
Treatment: A 
- Active TB or (considered) LTBI  consult pulmonologist for treatment, in some 
cases for 9 months (143). 
- During treatment of LTBI a biologic agent may be started after 1-3 months. 
There is no consensus about this issue, thus, it is recommended to start treatment in consultation with a pulmonologist (142, 143).  B 
- Preference of biologic agent: (see also table 37) Studies suggest that 
reactivation of latent TB is less common in etanercept compared to adalimumab or infliximab (143, 144). This could be related to the different mode of action 
and binding to TNF-alpha. For ustekinumab, at present, there is no available 
data.   
Table 37: Biologic agents classified by TB risk High risk (143, 144) Infliximab Adalimumab 
Prednisone ≥ 15mg/day Cytostatic agents Average risk (143, 144) Etanercept Low risk Methotrexate (one case reported at Lareb)  Cyclosporine (one case reported at Lareb) 
Too little evidence Ustekinumab  
Adalimumab 
H.B. Thio 
Table 38: Adalimumab 
Registration for psoriasis December 2007 (EMA) Recommended control parameters before starting treatment Complete blood count, liver enzymes, erythrocyte sedimentation (ESR) / CRP, serum creatinine, urine sediment, pregnancy test, HBV / HCV, HIV (prior to treatment). 
TB screening summarized: medical history, physical examination, chest X-ray, Mantoux 
test, Quantiferon test.  Recommended initial dosage Loading dosage: 80 mg subcutaneous Recommended maintenance dosage 40 mg subcutaneous 1x every 2 weeks Onset of effect After 4 weeks Response rate 53-80% PASI 75 24-52% PASI 90 Absolute contraindications (See SmPC) Hypersensitivity to adalimumab, severe active infections, chronic HBV, active TB, heart failure (NYHA III/IV), pregnancy or lactation, malignancy or lymphoproliferative 
disorder in recent history (< 5 years and excluded are BCC, KIN III, CIN III), demyelinating disorders, vaccination with live vaccines. Relative contraindications (See SmPC) Heart failure (NYHA I/II), hepatic and biliary disorders, HCV, PUVA >1000J/cm2 or 150-
200 treatments (especially when cyclosporine has been prescribed afterterwards), HIV or AIDS, Wegener’s 
granulomatosis. 
Most common adverse effects (See SmPC) ≥ 1/10: respiratory tract infections (including lower and upper respiratory tract infections, pneumonia, sinusitis, pharyngitis, nasopharyngitis, and viral herpes pneumonia), leucopenia (including neutropenia, agranulocytosis), anemia, increased lipid levels, headache, abdominal pains, nausea and vomiting, increased liver enzymes, rash (including scaly rash), myalgia, injection site reactions (including 
injection site erythema). 
≥ 1/100 to < 1/10: systemic infections (including sepsis, candidiasis and influenza), intestinal infections (including viral gastroenteritis), skin and subcutaneous infections (including paronychia, cellulitis, impetigo, necrotizing fasciitis and herpes zoster), etc. (see SMPC or 
http://www.huidarts.info/documents/uploaded_file.aspx?id=579) Important drug interactions Abatacept, Anakinra Special notes Vaccination with live vaccines should not be administered during treatment with a 
biologic. Depending on the drug’s half-life, the biologic must be stopped 4-8 weeks prior to immunization and may be restarted 2-3 weeks after vaccination. 
Conclusions of the Dutch guidelines 
  EL: 1 
Adalimumab is effective for the treatment of moderate to severe chronic 
plaque psoriasis in adult patients. After 16 weeks of treatment (Gorden 
et al., at week 12), PASI 75 was reached in 53-80% and PASI 90 in 24-
52% of patients with psoriasis treated with adalimumab.  
A2 Gordon et al., 2006 (145); Menter et al., 2008 (146); Saurat et al., 2008 
(103)  
Table 39: Important adverse effects of adalimumab 
Most frequently Injection site reactions, respiratory tract infections, headache, abdominal pains, nausea and vomiting, rash, myalgia, bone marrow depression 
Frequently (Severe) infections, benign tumors, skin cancer, mood swings (inter alia depression), anxiety, fatigue, sensory disturbances, migraine, dizziness, itch, pyrosis 
Sometimes Tuberculosis, lymphoma 
Rarely - 
Very rarely Drug-induced lupus, sudden cardiac death, multiple sclerosis  
Table 40: List of medication and drug interactions 
Medicine Type of drug interaction Anakinra Increased risk on serious infection Immunosuppressive mediation Increased immunosuppression 
(cyclosporine, other biologics) PUVA Risk of skin cancer  Instructions for adalimumab use  Prior to treatment 
• Objective assessment of psoriasis (such as PASI / BSA / PGA; arthritis) 
• Consider assessing HRQoL (e.g. DLQI, Skindex-29 or Skindex-17 or VAS) 
• Medical history and physical examination should be directed at therapeutic history, malignancies, infections, congestive heart failure and neurological symptoms 
• Recommended actions are: 
- Check for skin cancer 
- Check for lymphadenopathy 
- Laboratory controls (Table 41) 
- Chest X-ray, Mantoux test and QuantiFERON-TB Gold test 
- Pregnancy test 
• Contraception  During treatment 
• Objective assessment of psoriasis (such as PASI / BSA / PGA; arthritis) 
• Perform a TB screening annually (medical history, mantoux and IGRA) 
• Consider the assessment of HRQoL (e.g. DLQI, Skindex-29 or Skindex-17 or VAS) 
• Physical examination should be directed at malignancies, risk factors for serious infections, congestive heart failure and neurological symptoms 
• Recommended actions are: 
- Check for skin cancer 
- Check for lymphadenopathy 
- Laboratory controls (Table 41) 
- Urine sediment 
• Contraception  After treatment 
• After treatment with adalimumab physicians are advised to perform regular follow-ups with medical history and physical examination 
• Reliable contraceptives until 5 months after treatment, if indicated 
• Physicians are encouraged to document their patients’ parameters into registers (if available) to evaluate long-term efficacy and safety of biologics.  
Table 41: Laboratory controls 
Parameter Prior to 
treatment Treatment period (weeks) Thereafter once every 3 months   4 12  
Total blood count X X X X Liver enzymes X X X X Serum creatinine X X X X Urine sediment X X X X Erytrocyte sedimentation (ESR), CRP 
X X X X 
Pregnancy test (urine) X X X X 
HBV / HCV X    HIV X    
Further testing may be required based on clinical symptoms, risks and exposure  
Treatment recommendation 
Adalimumab is recommended for induction therapy (80 mg at week 0, followed by 40 mg every 2 weeks) in patients with 
moderate to severe chronic plaque psoriasis, when photo(chemo)therapy and conventional systemic treatments are ineffective, 
contraindicated, or not being tolerated. 
Etanercept 
T.E.C. Nijsten 
Table 42: Etanercept Registration for psoriasis September 2004 (EMA) Recommended control parameters before starting treatment Complete blood count, liver enzymes, ESR / CRP, serum creatinine, urine sediment, 
pregnancy test, HBV / HCV, HIV. TB screening summarized: medical history, physical examination, chest X-ray, 
Mantoux test, Quantiferon test.  Recommended initial dosage 2x25 mg/week, 1x50 mg/week or 2x50 
mg/week (week 0-12) Recommended maintenance dosage 2x25 mg/week, 1x50 mg/week or 2x50 mg/week Onset of effect After 6-8 weeks Response rate PASI 75 in 33 or 49% after 12 weeks 
(2x25 or 2x50 mg/week) Absolute contraindications (See SmPC) Hypersensitivity to etanercept, severe active infections, chronic HBV, active TB, heart failure (NYHA III/IV), pregnancy or 
lactation, malignancy or lymphoproliferative disorder in recent 
history (< 5 years and excluded are BCC, KIN III, CIN III), demyelinating disorders, vaccination with live vaccines. Relative contraindications (See SmPC) Heart failure (NYHA I/II), hepatic and biliary disorders, HCV, PUVA >1000J/cm2 or 150-200 treatments (especially when cyclosporine has been prescribed afterterwards), HIV or AIDS, Wegener’s 
granulomatosis. Most common adverse effects (See SmPC) ≥ 1/10: infections (including lower and upper respiratory tract infections, pneumonia, bronchitis, cystitis and skin infections), injection site reactions (including bleeding, bruising, erythema, 
itch, pain, swelling). 
≥ 1/100 to < 1/10: allergic reactions, auto-
antibody formation, pruritus, fever. Important drug interactions Anakinra, Abatacept, immunosuppressives 
(cyclosporine, other biologics), PUVA. Special notes Weight gain  
Conclusions of the Dutch guidelines    
Etanercept is effective for the treatment of moderate to severe plaque 
psoriasis in adult patients. At week 12, PASI 75 was reached in 30-34% 
and PASI 90 in 11% of patients when etanercept was prescribed in a 
 EL: 1 dosage of 2 x 25 mg per week. When 2 x 50 mg etanercept is administered, PASI 75 and PASI 90 are reached in 47-49% and 21% of 
patients, respectively, at week 12. These percentages increase with 10% 
at week 24.  
A2 Gottlieb et al., 2003 (147); Leonardi et al., 2003 (148); Tyring et al., 
2006 (149); Papp et al., 2005 (150)  
Table 43: Important adverse effects of etanercept 
Most frequently Infusion reactions, infections (upper respiratory tract, bronchitis, skin infections) 
Frequently Pruritus, antibody formation, allergy 
Sometimes Thrombocytopenia, urticaria, angioedema, severe infections (for example: pneumonia, cellulitis and sepsis), uveitis, Non-melanoma skin cancer, interstitial lung disease, rash 
Rarely Anemia, leucopenia, neutropenia, pancytopenia, vasculitis, subacute and 
discoid LE, demyelinating disease, TB reactivation, convulsions, heart failure, severe allergy, liver function abnormalities 
Very rarely Aplastic anemia  
Table 44: List of medication and drug interactions 
Medicine Type of drug interaction 
Anakinra Neutropenia and severe infections Immunosuppressive mediation (cyclosporine, other biologics) Increased immunosuppression PUVA Risk of skin cancer (especially squamous cell carcinoma)   Instructions for etanercept use  Prior to treatment 
• Objective assessment of psoriasis (such as PASI / BSA / PGA; arthritis) 
• Consider the assessment of HRQoL (e.g. DLQI, Skindex-29 or Skindex-17 or VAS) 
• Medical history and physical examination should be directed at therapeutic history, malignancies, infections, congestive heart failure and neurological symptoms 
• Recommended actions are: 
- Check for skin cancer 
- Check for lymphadenopathy 
- Laboratory controls (Table 45) 
- Chest X-ray, Mantoux test and QuantiFERON-TB Gold test 
- Pregnancy test 
• Contraception  During treatment 
• Objective assessment of psoriasis (such as PASI / BSA / PGA; arthritis) 
• Perform a TB screening annually (medical history, mantoux and IGRA) 
• Consider the assessment of HRQoL (e.g. DLQI, Skindex-29 or Skindex-17 or VAS) 
• Physical examination should be directed at malignancies, risk factors for serious infections, congestive heart failure and neurological symptoms 
• Recommended actions are: 
- Check for skin cancer 
- Check for lymphadenopathy 
- Laboratory controls (Table 45) 
- Urine sediment 
• Contraception  After treatment 
• After treatment with etanercept physicians are advised to perform regular follow-ups with medical history and physical examination 
• Physicians are encouraged to document their patients’ parameters into registers (if available) to evaluate long-term efficacy and safety of biologics.  
Table 45: Laboratory controls 
Parameter Prior to 
treatment Treatment period (weeks) Thereafter once every 3 months   4 6  
Total blood count X X X X Liver enzymes X X X X Serum creatinine X X X X Urine sediment X X X X Erytrocyte sedimentation X X X X 
(ESR), CRP Pregnancy test X X X X HBV / HCV X    HIV X    
Further testing may be required based on clinical symptoms, risks and exposure  
Treatment recommendation 
Etanercept is recommended for induction therapy (2 x 25 mg, 1 x 50 mg or 2 x 50 mg per week) (maximum of 24 weeks) in 
patients with moderate to severe chronic plaque psoriasis, when photo(chemo)therapy and conventional systemic treatments are 
ineffective, contraindicated, or not being tolerated. 
When induction therapy with etanercept is effective after 10-16 weeks, low dose etanercept (2 x 25 mg per week or 1 x 50 mg per 
week) should be prescribed as maintenance therapy. 
Infliximab 
M. de Groot 
Table 46: Infliximab Registration for psoriasis September 2005 (EMA) Recommended control parameters before starting treatment Complete blood count, liver enzymes, ESR / CRP, serum creatinine, urine sediment, 
pregnancy test, HBV / HCV, HIV. TB screening summarized: medical history, physical examination, chest X-ray, 
Mantoux test, Quantiferon test.  Recommended initial dosage 5 mg/kg body weight Recommended maintenance dosage 5 mg/kg body weight week 2, 6, and 
thereafter every 8 weeks Onset of effect After 2-5 weeks Response rate PASI 75 in 80% of patients after 10 weeks Absolute contraindications Hypersensitivity to infliximab, severe 
(See SmPC) active infections, chronic HBV, active TB, heart failure (NYHA III/IV), pregnancy or lactation, malignancy or lymphoproliferative disorder in recent 
history (< 5 years and excluded are BCC, KIN III and CIN III), demyelinating disorders, vaccination with live vaccines. Relative contraindications (See SmPC) Heart failure (NYHA I/II), hepatic and biliary disorders, HCV, PUVA >1000J/cm2 
or 150-200 treatments (especially when cyclosporine has been prescribed afterterwards), HIV or AIDS, Wegener’s granulomatosis. Most common adverse effects (See SmPC) ≥ 1/10: none ≥ 1/100 to < 1/10: viral infections (e.g., flu, viral herpes infection), serum sickness-like symptoms, headache, vertigo, dizziness, flush, lower respiratory 
tract infection (e.g., bronchitis, pneumonia), upper respiratory tract infections, sinusitis, dyspnoea, abdominal pains, diarrhea, nausea, dyspepsia, elevated transaminases, urticaria, rash, pruritus, hyperhidrosis, dry skin, infusion related reactions, chest pain, fatigue, fever Important drug interactions Abatacept, Anakinra Special notes Reliable contraceptives in fertile women 
until 6 months after infliximab treatment  
Conclusions of the Dutch guidelines   EL: 1 
Infliximab is effective for the treatment of moderate to severe chronic 
plaque psoriasis in adult patients. About 64% - 88% of patients treated 
with 5mg/kg infliximab reached PASI 75 at week 10. About 41% - 57% 
of patients treated with infliximab (5mg/kg) reached PASI 90 at week 
10.  
A2 Antoni et al., 2005 (151); Menter et al., 2007 (152); Reich et al., 2005 
(153); Gottlieb et al., 2004 (154)  
Table 47: Important adverse effects of infliximab 
Most frequently Infusion reactions, infections, nausea, diarrhea, difficulty breathing, dizziness, fatigue 
Frequently Headache, flushing, pruritus, urticaria, fever, elevated transaminases 
Sometimes Serum sickness-like disease, cutaneous lupus erythematosus, severe infections, anaphylactic reaction, circulation problems, depression  
Rarely Opportunistic infections, tuberculosis, pancytopenia, vasculitis, demyelinating diseases 
Very rarely Myelitis transversa, psoriasis (including pustular psoriasis), hepatocellular 
damage. In patients with Crohn’s disease 
and ulcerative colitis hepatosplenic T-cell 
lymphoma may be induced.   Instructions for infliximab use  Prior to treatment 
• Objective assessment of psoriasis (such as PASI / BSA / PGA; arthritis) 
• Consider the assessment of HRQoL (e.g. DLQI, Skindex-29 or Skindex-17 or VAS) 
• Medical history and physical examination should be directed at therapeutic history, malignancies, infections, congestive heart failure and neurological symptoms 
• Recommended actions are: 
- Check for skin cancer 
- Check for lymphadenopathy 
- Laboratory controls (Table 48) 
- Urine sediment 
- Chest X-ray, Mantoux test and QuantiFERON-TB Gold test 
- Pregnancy test 
• Contraception  During treatment 
• Objective assessment of psoriasis (such as PASI / BSA / PGA; arthritis) 
• Perform a TB screening annually (medical history, mantoux and IGRA) 
• Consider the assessment of HRQoL (e.g. DLQI, Skindex-29 or Skindex-17 or VAS) 
• Physical examination should be directed at malignancies, risk factors for serious infections, congestive heart failure and neurological symptoms 
• Recommended actions are: 
- Check for skin cancer 
- Check for lymphadenopathy 
- Laboratory controls (Table 48) 
- Urine sediment 
• Contraception  After treatment 
• After treatment with infliximab physicians are advised to perform regular follow-ups with medical history and physical examination 
• Reliable contraceptives until 6 months after cessation of treatment, if indicated 
• Physicians are encouraged to document their patients’ parameters into registers (if available) to evaluate long-term efficacy and safety of biologics.  
Table 48: Laboratory controls  
Parameter Prior to 
treatment Treatment period (weeks) Thereafter, prior to every infusion   4 6  
Total blood count X X X X Liver enzymes X X X X Serum creatinine X X X X Urine sediment X X X X Erytrocyte sedimentation X X X X 
(ESR), CRP Pregnancy test X X X X HBV / HCV X    HIV X    
Further testing may be required based on clinical symptoms, risks and exposure  
Treatment recommendation 
Infliximab is recommended for induction therapy when photo(chemo)therapy and conventional systemic treatments are 
ineffective, contraindicated, or not being tolerated. 
It is advised to prescribe infliximab 5mg/kg in patients with moderate to severe chronic plaque psoriasis at week 0, 2, 6, and every 
8 weeks thereafter. 
When induction therapy with infliximab is effective after 10-16 weeks, maintenance therapy with infliximab is recommended for 
every 8 weeks. 
It is advised to combine infliximab therapy with 7.5 mg methotrexate per week in order to prevent antibody formation and to 
lower the risk of infusion reactions. 
Ustekinumab 
Ph.I. Spuls, P.A. Poblete-Gutiérrez, J. de Bes 
Table 49: Ustekinumab Registration for psoriasis 20th November 2008 (EMA) Recommended control parameters before starting treatment Complete blood count, liver enzymes, ESR / CRP, serum creatinine, urine sediment, 
pregnancy test, HBV / HCV, HIV. TB screening summarized: medical history, physical examination, chest X-ray, 
Mantoux test, Quantiferon test.  Recommended initial dosage 45 mg, patients > 100 kg 90 mg at week 0, 
4 and 16 Recommended maintenance dosage 45 mg/12 weeks, patients > 100 kg 90 
mg/12 weeks 
Onset of effect After 2 weeks Response rate PASI 75 in 66-76% of patients Absolute contraindications (See SmPC) Hypersensitivity to ustekinumab, severe active infections, chronic HBV, active TB, heart failure (NYHA III/IV), pregnancy or lactation, malignancy or lymphoproliferative disorder in recent 
history (< 5 years and excluded are BCC, KIN III and CIN III), demyelinating disorders, vaccination with live vaccines. Relative contraindications (See SmPC) Heart failure (NYHA I/II) and a prior history of or increased risk for cardiovascular accident or acute 
myocardial infarction. Hepatic and biliary 
disorders, HCV, PUVA >1000J/cm2 or 150-
200 treatments (especially when cyclosporine has been prescribed afterterwards), HIV or AIDS, Wegener’s granulomatosis. Most common adverse effects (See SmPC) ≥ 1/10: nasopharyngitis and upper respiratory tract infections 
≥ 1/100 to < 1/10: inflammation of subcutaneous connective tissue (cellulitis), viral infection of the upper respiratory tract, hypersensitivity reactions (including rash and urticaria), depression, dizziness, headache, sore 
throat, stuffy nose, diarrhea, pruritus, back pain, myalgia, fatigue, erythema on injection site Important drug interactions Unknown Special notes Reliable contraceptives are mandatory in 
fertile women until 15 weeks after ustekinumab treatment  
Conclusions of the Dutch guidelines   EL: 1 
Ustekinumab is effective for the treatment of moderate to severe chronic 
plaque psoriasis in adult patients. PASI 75 was reached in 67% of 
patients treated with ustekinumab (45 mg at week 0, 4 and 16) at week 
12. PASI 75 was reached in 66-76% of patients treated with 
ustekinumab 90 mg (week 0, 4 and 16). A maximum effect was observed in more than three-quarters of the research population (PASI 75) after 
24 weeks.  
A2 Leonardi et al., 2008 (155); Papp et al., 2008 (132)  
Table 50: Important adverse effects of ustekinumab 
Most frequently Nasopharyngitis, upper respiratory tract infections, headache, arthralgia 
Frequently Cellulitis, viral infections of upper respiratory tract, depression, dizziness, headache, sore throat, stuffy nose, diarrhea, pruritus, back pain, myalgia, fatigue, erythema on injection site, 
urticaria 
Very rarely Severe infections or allergy  Instructions for ustekinumab use  Prior to treatment 
• Objective assessment of psoriasis (such as PASI / BSA / PGA; arthritis) 
• Consider the assessment of HRQoL (e.g. DLQI, Skindex-29 or Skindex-17 or VAS) 
• Medical history and physical examination should be directed at therapeutic 
history, malignancies, infections, TB, heart and kidney diseases and neurological symptoms 
• Recommended actions are: 
- Check for skin cancer 
- Check for lymphadenopathy 
- Laboratory controls (Table 51) 
- Urine sediment 
- Chest X-ray, Mantoux test and QuantiFERON-TB Gold test 
- Vaccinations in concordance with the National Immunization Program 
- Pregnancy test 
• Reliable contraceptives in fertile women during treatment and until 15 weeks after cessation of treatment  
During treatment (every 3 months) 
• Objective assessment of psoriasis (such as PASI / BSA / PGA; arthritis) 
• Perform a TB screening annually (medical history, mantoux and IGRA) 
• Consider the assessment of HRQoL (e.g. DLQI, Skindex-29 or Skindex-17 or VAS) 
• Recommended actions are: 
- Check for skin cancer 
- Laboratory controls (Table 51) 
- Urine sediment  After treatment 
• Follow-up visits for assessing symptoms of psoriasis 
• Reliable contraceptives until 15 weeks after cessation of treatment, if indicated 
• Physicians are encouraged to document their patients’ parameters into registers (if available) to evaluate long-term efficacy and safety of biologics.  
Table 51: Laboratory controls 
Parameter Prior to 
treatment After 4 weeks Thereafter once every 12 weeks 
Total blood count X X X Liver enzymes X X X Serum creatinine X X X Urine sediment X X X Erytrocyte sedimentation (ESR), CRP 
X X X 
Pregnancy test X X X HBV / HCV X   HIV X   
Further testing may be required based on clinical symptoms, risks and exposure 
Considerations when prescribing biologics 
T.E.C. Nijsten 
The following table highlights the considerations per biologic. 
Table 52: Considerations when prescribing biologics 
Etanercept (E) Adalimumab (A) Infliximab (I) Ustekinumab (U) Less efficacy compared to A, I 
and U. However, maximum efficacy may be reached after 24 weeks 
Higher efficacy compared to E 
(after 12 and 24 weeks) 
Higher efficacy compared to E 
(after 12 and 24 weeks) 
Higher efficacy compared to E (after 
12 and 24 weeks) 
  Fast initial response  Less effective than U No head-to-head trials with this biologic 
No head-to-head trials with this biologic 
More effective than E 
Drug survival rate below I (daily practice data) 
Drug survival rate below I (daily practice data) 
Highest drug survival rate compared to A and E (daily practice data) 
Drug survival rate is 
high during 1 year (daily practice data) 
Injection side reaction Injection side reaction Infusion reaction Injection side reaction 
Thrombocytopenia, leucopenia and pancytopenia 
Thrombocytopenia, leucopenia and pancytopenia 
Thrombocytopenia, leucopenia and pancytopenia 
Thrombocytopenia, leucopenia and pancytopenia 
Less TB reactivation compared to A and I More TB reactivation compared to E 
More TB reactivation compared to E 
Little long-term experience 
Non-neutralizing antibody formation Neutralizing antibody formation, possibly clinically relevant 
Neutralizing antibody formation, clinically relevant 
 
High dosage (2x50 mg/week) leads to high costs 
Loading dosage at start increases cost 
at start. 
In extreme obese 
patients (> 100kg) 
costs will rise. Loading dosage at start increases cost 
at start. 
In extreme obese 
patients (> 100kg) 
costs will rise. Loading dosage at start increases cost 
at start. Subcutaneously Subcutaneously Intravenously Subcutaneously    Long treatment 
interval (3 months). (Higher user friendliness) Daily practice data indicate biologics to be less effective when compared to data from 
randomized controlled trials. Hence, the dosage of biologics is higher in daily practice. 
This table is a summary of the paragraph “considerations when prescribing biologics” within the Dutch guidelines on the treatment of psoriasis 
2011 (http://www.huidarts.info/documents/uploaded_file.aspx?id=579). The content of this table is based upon the following references: [125-
127, 134, 156-160]. 
Conclusions 
Adalimumab or low-dose etanercept (1x50 mg/week) are the preferred first-choice treatments in otherwise healthy, biologic-naïve 
psoriasis patients. Adalimumab seems to be more effective than etanercept in the short-term, but may be related to clinically 
relevant antibody formation. Infliximab is preferred in acute situations (e.g., severe exacerbation of plaque psoriasis, off-label for 
psoriatic erythroderma or generalized pustular psoriasis) because of high efficacy and fast clinical response, followed by a 
maintenance dosage of this agent. Also, infliximab is important in patients not responding to other TNF-alpha agents. Although 
ustekinumab is highly effective, the working group holds the opinion that until long-term efficacy and safety are elucidated this 
agent should be reserved for patients responding insufficiently to TNF-alpha antagonists. 
3. Treatment of psoriasis of the face and flexures 
P.C.M. van de Kerkhof, C.L.M. van Hees 
Epidemiology 
Conclusions of the Dutch guidelines 
    
EL: 3 
Psoriasis of the face is present in 17-46% and psoriasis of the flexures in 
6.8-36% of psoriasis patients. Hence, psoriasis cannot be regarded as a 
rare manifestation in these areas.  
C Fauéré et al., 2005 (161); Dubertret et al., 2006 (162); van de Kerkhof et 
al., 2000 (163); Farber et al., 1968 (164); Farber et al., 1974 (165); Wang 
et al., 2005 (166); Nanda et al., 1990 (167); Puissant, 1970 (168); Nyfors et 
al., 1975 (169) 
D van de Kerkhof et al., 2007 (10)  
Recommendation  
It is recommended to further study the efficacy and safety of treatments (preferably by randomized, double blind, controlled 
trials), given the frequency of psoriasis of the face and flexures. 
Clinical signs 
Conclusions of the Dutch guidelines   EL: 4 
Psoriasis of the face is a prognostic marker for a severe form of psoriasis. 
Psoriasis of the flexures is not a prognostic marker.  
C Park et al., 2004 (170) 
D van de Kerkhof et al., 2007 (10)    EL: 4 
Psoriasis of the face and psoriasis of the flexures should not be considered two different disease entities, but as a variation of 
localization of the same disease.  
D van de Kerkhof et al., 2007 (10)  
  EL: 3 
Clinical signs of facial psoriasis suggest there are three forms: hairline psoriasis, sebo-psoriasis and true facial psoriasis.  
C Woo et al., 2008 (171) 
D van de Kerkhof et al., 2007 (10)    EL: 4 
Otitis externa and ocular manifestations may drastically decrease quality 
of life and should therefore not be neglected.  
D van de Kerkhof et al., 2007 (10)  
Pathogenetic aspects 
Conclusions of the Dutch guidelines   EL: 3 
Evidence is small to absent on the role of microbiological factors in the 
pathogenesis of psoriasis of the face and flexures.  
C Rosenberg et al., 1989 (172) 
D van de Kerkhof et al., 2007 (10)    EL: 3 
The reaction to UV radiation differs between patients with facial 
psoriasis. At least 5% of psoriasis patients has photosensitive psoriasis.  
C Farber et al., 1968 (164); Farber et al., 1974 (165); Lane et al., 1937 
(173); Lomholt et al., 1963 (174); Braun-Falco et al., 1972 (175) 
D van de Kerkhof et al., 2007 (10) 
 
Recommendation 
It is recommended to exclude photosensitive diseases such as lupus erythematosus and polymorphic light eruption in patients with 
photosensitive psoriasis. 
Antimicrobial treatment 
Conclusions of the Dutch guidelines   EL: 3 
There is no evidence that antimicrobial treatment is effective for 
psoriasis of the flexures. 
 
C Leigheb et al., 2000 (176)    EL: 3 
There is evidence antifungal treatment may be effective for sebo-psoriasis of the face.  
C Doering., 1985 (177); Faergemann, 1985 (178)  
Considerations 
The efficacy of antiseptic, antibacterial, and antifungal treatments has sparsely been investigated in comparing studies. 
Randomized and double blind trials are lacking. 
Treatment recommendation 
Antimicrobial treatment is not indicated for the treatment of psoriasis of the face and flexures. 
 Dithranol and coal tar 
Conclusions of the Dutch guidelines   EL: 3 
The efficacy of dithranol combined with coal tar is similar as for fluocinolone acetonide cream.  
B Heller, 1989 (179)  
Considerations 
The evidence of the efficacy of dithranol is also being supported by decades of clinical experience. 
 Skin irritation and stains in textile limit the use of these treatments. 
Treatment recommendation 
Discoloration and skin irritation limit the use of dithranol and coal tar. Dithranol and coal tar are not indicated for first-line 
therapy, except in cases in which first-line therapies fail. 
Topical corticosteroids 
Conclusions of the Dutch guidelines    EL: 3 
Evidence about the efficacy and safety of topical corticosteroids comes from a non-comparative study (topical corticosteroids until 12 weeks) and a double blind, randomized vehicle-controlled study (topical 
corticosteroids during 4 weeks).  
B Kreuter et al., 2006 (180) 
C Lebwohl et al., 2001 (181)  
 Considerations 
Textbooks state that low-potent (class 1-2) topical corticosteroids are effective and safe, whereas mid-potent (class 2-3) topical 
corticosteroids induce perioral dermatitis and striae, especially during long-term use. 
Treatment recommendation 
Topical corticosteroids class 1-2 (low-potency) are first-choice treatments for psoriasis of the face and flexures during a limited 
treatment period. Subsequently, topical non-steroidal agents should be prescribed. 
Vitamin D3 analogues 
Conclusions of the Dutch guidelines    EL: 2 
Vitamin D analogues are effective for the treatment of psoriasis of the 
face and flexures.  
A2 Liao et al., 2007 (182) 
B Ortonne et al., 2003 (183) 
C Duweb et al., 2003 (184); Kienbaum et al., 1996 (185); Langer et al., 
1996 (186)   EL: 3 Calcitriol is superior over calcipotriol regarding safety profile.  
B Ortonne et al., 2003 (183)  
Treatment recommendations 
Vitamin D3 analogues are first-choice treatments for psoriasis of the face and flexures. Calcitriol induces less adverse effects, 
such as erythema and irritation, than calcipotriol. 
Calcineurin inhibitors 
Conclusions of the Dutch guidelines    
EL: 1 
The efficacy of calcineurin inhibitors for the treatment of psoriasis of the face and flexures has been assessed in 4 independent A2-studies (2 placebo-controlled studies, 1 comparative study with clobetasone 
butyrate and 1 comparative study with calcitriol).  
A2 Lebwohl et al., 2004 (187); Gribetz et al., 2004 (188); Kleyn et al., 2005 
(189); Liao et al., 2007 (182)    
Considerations 
Calcineurin inhibitors are not registered for this treatment indication. 
Treatment recommendations 
Low-potent (class 1-2) topical corticosteroids during 2-4 weeks are the first-choice treatment of psoriasis of the face and flexures. 
Calcineurin inhibitors or Vitamin D3 analogues may also be prescribed. Calcineurin inhibitors may be used for long-term 
treatment. 
Photo(chemo)therapy 
Conclusions of the Dutch guidelines 
  EL: 4 
No studies have been conducted measuring the efficacy and safety of 
photo(chemo)therapy. However, clinical experience shows these 
treatments improve psoriasis of the face and flexures.  
D van de Kerkhof et al., 2007 (10)  
Treatment recommendations 
When topical therapies provide insufficient disease control, phototherapy is an option for the treatment of psoriasis of the face and 
flexures. 
Systemic therapies 
Conclusions of the Dutch guidelines   EL: 4 
No studies have been conducted measuring the efficacy and safety of methotrexate, cyclosporine, acitretin, fumaric acid esters and biologics 
for the treatment of psoriasis of the face and flexures. However, clinical 
experience shows these treatments improve psoriasis in these locations.  
D van de Kerkhof et al., 2007 (10)    
EL: 3 
There is evidence available indicating botulinum toxin is effective for the 
treatment of psoriasis of the flexures.  
C Zanchi et al., 2008 (190)  
Considerations 
Botulinum toxin is not registered for the treatment of psoriasis. The costs of this treatment are substantial. 
Treatment recommendations 
When topical therapies provide insufficient disease control, systemic therapies are an option.  
4. Treatment of childhood psoriasis  
M.M.B. Seyger 
Introduction 
All drugs mentioned in these guidelines have not been registered for the treatment of childhood psoriasis. Thus, usage of these 
drugs is off-label, with the exception of etanercept, which is registered for plaque psoriasis in children aged eight years or older. 
Off-label use of drugs is not uncommon, according to the Medicine Evaluation Board (MEB; Netherlands: CBG) and Inspection 
for Health Care (IGZ), if justified. The treating physician is obligated to inform the patient about the advantages and 
disadvantages of off-label drug use. 
Topical corticosteroids 
Conclusions of the Dutch guidelines   
EL: 3 
Halobetasol cream 0.05% and clobetasol proprionate emulsion 0.05% 
twice daily may be effective treatments for childhood psoriasis. 
Reported adverse effects during treatment were relatively mild.  
C Herz et al., 1991 (191); Kimbal et al., 2008 (192) 
D Feicht, 1982 (193)  
Considerations 
Published literature on the use of topical corticosteroids in childhood psoriasis is scarce. The number of treated patients is low and 
the treatment period short. Also, different vehicles were being used. Nonetheless, topical corticosteroids are important in the 
physician’s treatment arsenal for treating childhood psoriasis. 
Treatment recommendations 
The use of topical corticosteroids is rewarding in childhood psoriasis. It is recommended to use topical corticosteroids of class 2-3 
(mild-potency). 
Vitamin D3 analogues 
Conclusions of the Dutch guidelines   
EL: 3 
Calcipotriol is an effective and mostly well tolerated treatment option for 
plaque type childhood psoriasis. Adverse effects are mild.  
A2 Oranje et al., 1997 (194)  
  
EL: 3 
Calcitriol seems to be an effective treatment for childhood psoriasis with 
mild adverse effects.  
B Perez et al., 1995 (195)  
Considerations 
Both calcipotriol and calcitriol are not registered for use in children. Calcipotriol is no longer available as monotherapy in the 
Netherlands. 
Treatment recommendations 
Given the efficacy and mild adverse effect profile of Vitamin D3 and analogues (calcipotriol), these agents are recommended as 
first-choice therapy for childhood psoriasis. A combination with topical corticosteroids class 2-3 (mild potency) is recommended. 
Calcineurin inhibitors 
Conclusions of the Dutch guidelines   
EL: 3 
Tacrolimus 0.1% seems to be effective and safe for short-term treatment of childhood psoriasis of the face and flexures. Long-term efficacy has 
not been described in studies.  
C Brune et al., 2007 (196); Steele et al., 2005 (197)    
EL: 3 
Due to small numbers of treated patients, no conclusions can be drawn on the use of pimecrolimus for childhood psoriasis.  
C Amichai, 2004 (198); Mansouri et al., 2006 (199)  
Considerations 
Studies covered by these guidelines only describe the efficacy of 0.1% tacrolimus in children with psoriasis of the face and 
flexures. Calcineurin inhibitors are not registered for this treatment indication. In children (≤ 16 years) with eczema, tacrolimus 
0.03% is registered. 
Treatment recommendations 
It is recommended to consider treatment with tacrolimus 0.03% or 0.1% in children with therapy resistant psoriasis of the face and 
flexures. 
Dithranol 
Conclusions of the Dutch guidelines   
EL: 3 
Dithranol is effective and safe for treatment of childhood psoriasis.  
C Zvulunov et al., 1994 (200); Guerrier et al., 1983 (201) 
D Schubert et al., 2007 (202)  
Considerations 
To reduce the risk of adverse effects (discolorations and skin irritation) dithranol should be used in a daycare unit setting. This 
also increases compliance and guarantees a more effective treatment regimen.  
Treatment recommendations 
It is strongly recommended to prescribe dithranol treatment for children with psoriasis if treatment with topical corticosteroids and 
vitamin D3 analogues failed. This should preferably take place in a daycare unit. 
 Phototherapy 
Conclusions of the Dutch guidelines   
EL: 3 
Narrowband UVB treatment for children with plaque psoriasis or guttate psoriasis has positive results and a relatively mild adverse effect profile 
during a mean treatment period of 12 weeks.  
C Al-Fouzan et al., 1995 (203); Jain et al., 2007 (204); Jury et al., 2006 
(205); Pasic et al., 2003 (206); Tay et al., 1996 (207)  No conclusion possible 
Evidence on the efficacy of PUVA treatment for childhood psoriasis is too 
limited.  
D Kim et al., 1998 (208); Thappa et al., 2006 (209)  
Considerations 
Uncertainty persists on the long-term safety of UVB phototherapy. UVB therapy results in actinic damage and premature skin 
aging. UVB is carcinogenic. Oral PUVA has a carcinogenic effect. 
Treatment recommendations 
It is recommended to limit the use of UVB phototherapy in children with psoriasis. Especially in children less than 12 years of age 
and a fair skin type, UVB should be considered with great care. PUVA therapy is contraindicated in children with psoriasis given 
its carcinogenic effect. 
Antibiotics 
Conclusions of the Dutch guidelines   
EL: 3 
The efficacy of oral antibiotics and its use in children with guttate 
psoriasis remains controversial.  
C Patrizi et al., 1994 (210) 
D Pacifico, 1993 (211)  
Considerations 
If, on anamnesis, the psoriatic plaques erupted after a severe throat infection or the psoriasis deteriorated after a throat infection, it 
is recommended to perform a throat culture. 
Treatment recommendations 
When, on anamnesis, a throat infection may have induced or worsened the psoriasis and the performed throat culture is positive, it 
is recommended to consider the use of oral antibiotics. 
Retinoids 
Conclusions of the Dutch guidelines   
EL: 3 
Etretinate is effective in treating pustular or erytrodermic psoriasis. However, adverse effects are frequently encountered.  
C Rosinska et al., 1988 (212); van de Kerkhof, 1985 (213); Pavicic et al., 
1986 (214); Kim et al., 1991 (215); van der Rhee et al., 1980 (216) No The use of acitretin in childhood psoriasis has not been thoroughly 
conclusion possible studied. Therefore, no conclusions can be stated in these guidelines. However, given the positive experiences with etretinate, it is likely that acitretin is also effective in pustular and erythrodermic childhood 
psoriasis.   
Considerations 
Etretinate is no longer available. Acitretin is a metabolite of etretinate, therefore, the efficacy of acitretin is probably similar to 
etretinate. Considerations about general safety are described in the chapter of retinoids in the full Dutch S3-guidelines: 
http://www.huidarts.info/documents/uploaded_file.aspx?id=579. Special attention should be given to the occurrence of skeletal 
toxicities in children on long-term retinoid therapy [217]. 
Treatment recommendations 
It is recommended to consider the use of acitretin in children with pustular or erytrodermic psoriasis. It is firmly recommended not 
to treat adolescent women, given the potential teratogenic effects. 
Treatment with acitretin may be considered in other types of childhood psoriasis. 
Cyclosporine 
Conclusions of the Dutch guidelines   
EL: 3 
The described efficacy of cyclosporine treatment in childhood psoriasis 
is ambiguous. Safety aspects were sparsely described.  
C Mahe et al., 2001 (218); Kilic et al., 2001 (219); Alli et al., 1998 (220); 
Torchia et al., 2006 (221)    
Considerations 
Adverse effects of cyclosporine in children with psoriasis were sparsely described in studies. In children with atopic dermatitis, 
this agent was well tolerated for a period of one year [222]. Given the potential cumulative toxicity, especially children should be 
treated with caution [223]. 
Treatment recommendations 
Given the previous considerations and the contradictive evidence on cyclosporine for childhood psoriasis, it is recommended to 
use this agent only in exceptional cases. 
Methotrexate 
Conclusions of the Dutch guidelines 
   
EL: 3 
Methotrexate is effective for the treatment of moderate to severe 
childhood psoriasis. Most evidence is on plaque psoriasis. Short-term 
adverse effects are relatively mild and can easily be treated.  
C Collin et al., 2006 (224); Kaur et al., 2008 (225); Kumar et al., 1994 
(226); Kalla et al., 1996 (227); Dogra et al., 2004 (228); Dogra et al., 2005 
(229); Ivker et al., 1993 (230)     
Considerations 
Long-term safety of methotrexate for childhood psoriasis has not been studied. However, this drug has been used for decades for 
the treatment of juvenile idiopathic arthritis without severe adverse effects. Therefore, this treatment is considered safe [231]. 
Treatment recommendations 
Methotrexate is recommended as first-choice systemic treatment in children with moderate to severe plaque psoriasis. Dosage is 
between 0.2-0.4 mg/kg/week. Folic acid 5mg should be administered 24 hours after methotrexate intake. Methotrexate should not 
be administered with milk products as this negatively affects its efficacy. 
Biologics 
Conclusions of the Dutch guidelines   
EL: 3 
Etanercept is effective for the treatment of plaque psoriasis in children. 
Dosage was 0.8 mg/kg/week. Short-term adverse effects are usually 
infections.  
A2 Paller et al., 2008 (232)  No conclusion possible 
Infliximab seems effective for induction of remission. However, firm conclusions cannot be made on the results of 4 patients.  
D Pereira et al., 2006 (233); Farnsworth et al., 2005 (234); Menter et al., 
2004 (235); Weishaupt et al., 2007 (236)  
Considerations 
Knowledge on long-term adverse effects of biologics is insufficient. It is unknown whether biologics increase the risk of 
lymphoma and skin cancer in psoriasis patients. The safety and effectiveness of etanercept was registered for children with 
juvenile idiopathic arthritis during 8 consecutive years. In these 8 years, the authors found no increase of severe adverse effects 
[231]. 
Treatment recommendations 
Given the uncertainty concerning long-term safety of biologics, care should be taken in prescribing these agents in children with 
moderate to severe psoriasis. Etanercept is recommended when topical therapies, e.g. dithranol, as well as UVB (in older children) 
and methotrexate are ineffective, contraindicated, or not being tolerated. 
The working group holds the opinion that children treated with etanercept should be registered in a national database to evaluate 
long-term safety. 
Other topical and systemic therapies 
Conclusions of the Dutch guidelines No conclusion possible 
No conclusions can be drawn on the efficacy and safety of Chinese drugs, excimer laser, tazarotene, wratizolin, fumaric acid esters, dapsone, 
prednisone, tonsillectomy and colchicine.   
C Lin et al., 2006 (237); Pahlajani et al., 2005 (238); Diluvio et al., 2007 
(239); Michalowski et al., 1983 (240); Gunther et al., 2004 (241); Yu et al., 
2001 (242); Fernandes-EI et al., 2000 (243); Tsuge et al., 1995 (244); 
McMillin et al., 1999 (245); Hone et al., 1996 (246); Wahba et al., 1980 
(247); Zachariae et al., 1982 (248)  
Considerations 
None 
Treatment recommendations 
No conclusions can be drawn from the literature on the efficacy and safety of other therapies. These therapies are not 
recommended. 
5. The patient’s perspective 
J. de Korte, O.D. van Cranenburgh 
The experiences and opinions of patients with chronic skin diseases are becoming increasingly important for the assessment of 
their general and skin-related health status, and for the treatment of their skin disease. These patients’ perspectives are generally 
captured with so-called Patient Reported Outcomes (PROs). PROs are reports or assessments of any aspect of a patient’s health 
status and/or treatment impact that are directly expressed by the patient, i.e. without the interpretation of others [249]. Examples of 
PROs are: disease severity, health-related quality of life, cost-benefit, safety, compliance, treatment preference, and satisfaction 
with treatment.  
Health-related quality of life (HRQoL) of patients with psoriasis, i.e. the physical, emotional and social functioning and well being 
of patients, has been referred to throughout the Dutch S3-guidelines on the treatment of psoriasis 2011. The practice guidelines 
‘Photo(chemo)therapy and systemic therapy in severe chronic plaque-psoriasis’ 2003 (updated 2005 and 2009) also addressed 
that, in exceptional cases, patients with less severe psoriasis may be prescribed a biological agent when there is a considerable loss 
of quality of life (Skindex-29 ≥ 35, combined with a PASI ≥ 8) (6). 
In order to gain insight into psoriasis patients’ satisfaction with treatment, we conducted a cross-sectional, national, web-based, 
survey. Aims of this survey were to assess the degree of patients’ satisfaction with prior and current dermatological treatments and 
to study how patients value 1) effectiveness, 2) safety, 3) convenience and 4) organization of treatment, 5) information about 
treatment,and 6) the doctor-patient relationship. 
Our study comprised 2070 patients (response rate: 43%), aged ≥ 18 years, with a self-reported diagnosis of psoriasis and treated or 
being treated with topicals, phototherapy, and/or systemic therapies. The questionnaire survey was preceded by literature search, 
results from a focus group session (N=9), and results from a previous survey (conducted for the first Dutch evidence-based 
psoriasis guidelines, 2005). The literature search revealed the importance of specifying domains of treatment satisfaction [250, 
251].  
The questionnaire survey was comprised of 27, mainly multiple-choice questions on patient characteristics, disease duration and 
severity, prior and current treatments, as well as generic and specific treatment satisfaction. Questions about treatment satisfaction 
were answered on a 5-point scale: 1 = very dissatisfied and 5 = very satisfied. The group of “Satisfied patients” was defined as the 
group of patients with scores of 4 and 5 and the group of “Dissatisfied patients” as the group of patients with a score of 1. Patients 
with scores 2 and 3 were excluded from analysis. 
For an extensive report on methodology, patient characteristics, data analysis, and results we refer to the complete Dutch S3-
guidelines on the treatment of psoriasis 2011: http://www.huidarts.info/documents/uploaded_file.aspx?id=579. An international 
peer-reviewed publication is in preparation [252]. 
Conclusions  
Following conclusions and recommendations are based on the research report.       
EL: 3 
1. About 1 out of 3 psoriasis patients (32.4%) was satisfied with prior 
treatments. About 1 out of 14 patients (7.0%) was dissatisfied with prior 
treatments.  
2a. About half of psoriasis patients (53.8%) was satisfied with their 
current treatment. Patients with topical therapies were least satisfied, 
patients with systemic therapies were most satisfied.  
2b. Patients receiving a topical therapy were least satisfied with 
effectiveness and convenience of treatment. Patients receiving 
phototherapy were least satisfied with effectiveness of treatment. Patients with systemic treatment were least satisfied with safety of treatment.  
3. Patients value the effectiveness of treatment as the most important 
domain of satisfaction. The doctor-patient relationship was valued as 
important as treatment safety, and more important than convenience.  
Recommendations on quality of life and treatment satisfaction 
1. In dermatological practice, it is recommended to explicitly address the influence of psoriasis on quality of life by: 
a) Asking patients directly about their quality of life or by means of standardized questionnaires such as the DLQI or 
Skindex, if applicable and relevant. 
b) Modifying treatment and care, if necessary, based on current evidence. 
2. In dermatological practice, it is recommended to explicitly address treatment satisfaction by: 
a) Asking patients directly about their treatment satisfaction (general as well as specific) regarding: 1) effectiveness, 2) 
safety, 3) convenience, 4) organization of treatment, 5) information about treatment, and 6) the doctor-patient 
relationship). 
b) Modifying treatment and care, if necessary, based on current evidence. 
3. Additionally, it is recommended to professionals to determine norms or cut-off points for the interpretation of scores of 
satisfaction and dissatisfaction with treatment, based on evidence, suitability, and feasibility. 
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